101 results on '"Velciov, S."'
Search Results
2. FP353Liver fibrosis as evaluated by transient elastography is not correlated with CKD development and severity in DM2 patients
- Author
-
Adalbert, Schiller, primary, Marc, L, additional, Timar, R, additional, Popescu, A, additional, Sirli, R, additional, Nistorescu, S, additional, Gadalean, F, additional, Mihaescu, A, additional, Schiller, O, additional, Bob, F, additional, Grosu, I, additional, Velciov, S, additional, and Sporea, I, additional
- Published
- 2019
- Full Text
- View/download PDF
3. SP442THE TIME FRAME OF VASCULAR REMODELLING IS DISSOCIATED WITHIN THE BRAIN AND THE KIDNEY AND MAY BE EXPLAINED BY THE VARIABILITY OF miRNAs EXPRESSION IN TYPE 2 DIABETES MELLITUS PATIENTS
- Author
-
Petrica, L, primary, Pusztai, A-M, additional, Vlad, M, additional, Vlad, A, additional, Gadalean, F, additional, Dumitrascu, V, additional, Vlad, D, additional, Velciov, S, additional, Gluhovschi, C, additional, Bob, F, additional, Ursoniu, S, additional, Petrica, M, additional, Matusz, P, additional, Cretu, O, additional, Milas, O, additional, Secara, A, additional, Simulescu, A, additional, Popescu, R, additional, and Jianu, C D, additional
- Published
- 2018
- Full Text
- View/download PDF
4. Cerebral Microangiopathy in Patients with Non-insulin-dependent Diabetes Mellitus
- Author
-
Petrica, L., Petrica, M., Munteanu, M., Adrian Vlad, Bob, F., Gluhovschi, C., Gluhovschi, G., Jianu, C., Schiller, A., Velciov, S., Trandafirescu, V., and Bozdog, G.
- Subjects
Carotid Artery Diseases ,Inflammation ,Male ,Time Factors ,Romania ,General Medicine ,Middle Aged ,Prognosis ,Risk Assessment ,Diabetes Mellitus, Type 2 ,Risk Factors ,Ultrasonography, Doppler, Pulsed ,Case-Control Studies ,Prevalence ,Humans ,Female ,Carotid Artery, Internal ,Diabetic Angiopathies - Abstract
Introduction: The aim of the study was to evaluate cerebral microangiopathy in type 2 non-insulin-dependent diabetes mellitus (NIDDM) patients and to establish potentially conducive factors. Materials and Methods: A group of 34 patients with NIDDM and 31 gender- and age-matched normal controls (NC) were assessed by extracranial Doppler ultrasound, in order to evaluate the pulsatility index (PI) and the resistance index (RI) in the internal carotid arteries (ICAs); transcranial Doppler was utilised to assess the same parameters in the middle cerebral arteries (MCAs). All patients underwent screening for favouring factors for cerebral vascular remodelling. Results: Of the 34 NIDDM patients, 21 patients (61.76%) (subgroup A) presented with microangiopathic complications [of these, 19 patients (90.46%) had diabetic nephropathy (DN)] versus 13 NIDDM patients (38.24%) (subgroup B) without complications. In subgroup A, 16 patients (76.19%) had PI >1 and RI >0.7 in the ICAs and MCAs (changes consistent with cerebral microangiopathy) versus 5 patients (35.46%) in subgroup B, and no modifications in NC. Of the 19 patients with DN, 14 patients (73.68 %) had impaired haemodynamic indices. Univariate regression analysis showed the following risk factors for the cerebral haemodynamics changes: fibrinogen (F) (OR = 3.11), C-reactive protein (CRP) (OR = 2.40), duration of DM (OR=2.40), proteinuria (OR = 1.80), serum creatinine (OR = 1.66). Multivariate regression analysis showed as predictors for impaired haemodynamic indices: duration of DM (HR =1.70), proteinuria (HR = 1.70). The haemodynamic indices in the ICAs correlated with duration of DM (r = 0.87, P
- Published
- 2007
- Full Text
- View/download PDF
5. Glycated peptides are associated with proximal tubule dysfunction in type 2 diabetes mellitus
- Author
-
Petrica, L., Vlad, A., Gluhovschi, G., Zamfir, A., Popescu, C., Gadalean, F., Dumitrascu, V., Vlad, D., Popescu, R., Velciov, S., Gluhovschi, C., Bob, F., Milas, O., and Sorin Ursoniu
- Subjects
Original Article - Abstract
Background: Advanced glycation end-products have been involved in the pathogenesis of proximal tubule dysfunction which characterizes diabetic tubulopathy. Methods: A total of 76 Type 2 diabetes mellitus patients and 28 healthy controls were evaluated concerning a potential association of glycated peptides with proximal tubule dysfunction by assessing urine albumin:creatinine ratio, urinary alpha1-microglobulin, urinary neutrophil gelatinase-associated lipocalin, plasma and urinary advanced glycation end-products, plasma asymmetric dimethyl-arginine, serum cystatin C. Fully automated chip-nanoelectrospray ionization and high-capacity ion trap multistage mass spectrometry characterized the urinary proteomic profile. Results: The urinary glycated proteins displayed a molecular weight of 15,121.4 Da in normoalbuminuric patients and of 30,180.4 Da in microalbuminuric patients. Urinary alpha1-microglobulin and neutrophil gelatinase-associated lipocalin correlated with urinary advanced glycation end-products (R2=0.586; R2=0.415), urine albumin: creatinine ratio (R2=0.292; R2=0.116), estimated glomerular filtration rate (R2=0.172; R2=0.135), serum cystatin C (R2=0.146; R2=0.129), but not with asymmetric dimethyl-arginine. In multivariable regression analysis models, the correlations for urinary alpha1-microglobulin and neutrophil gelatinase-associated lipocalin remained significant with urine albumin: creatinine ratio, urinary advanced glycation end-products, estimated glomerular filtration rate (P
- Published
- 2015
6. Glycated peptides induce endothelial dysfunction in the brain vasculature in normoalbuminuric patients with type 2 diabetes mellitus
- Author
-
Petrica, L., primary, Vlad, A., additional, Petrica, M., additional, Jianu, D.C., additional, Zamfir, A., additional, Popescu, C., additional, Gluhovschi, G., additional, Gadalean, F., additional, Dumitrascu, V., additional, Gluhovschi, C., additional, Velciov, S., additional, Bob, F., additional, Vlad, D., additional, Milas, O., additional, Balgradean, C., additional, and Ursoniu, S., additional
- Published
- 2013
- Full Text
- View/download PDF
7. Clinical Nephrology - Lab methods and other markers
- Author
-
Kleophas, W., primary, Bieber, B., additional, Robinson, B., additional, Duttlinger, J., additional, Fliser, D., additional, Lonneman, G., additional, Rump, L., additional, Pisoni, R., additional, Port, F., additional, Reichel, H., additional, Daniela, R., additional, Ciocalteu, A., additional, Checherita, I. A., additional, Peride, I., additional, Spataru, D. M., additional, Niculae, A., additional, Laetitia, K., additional, Amna, K., additional, Laurence, D., additional, Aoumeur, H.-A., additional, Flamant, M., additional, Haymann, J.-P., additional, Letavernier, E., additional, Vidal-Petiot, E., additional, Boffa, J.-J., additional, Vrtovsnik, F., additional, Bianco, F., additional, Pessolano, G., additional, Carraro, M., additional, Panzetta, G. O., additional, Ebert, N., additional, Gaedeke, J., additional, Jakob, O., additional, Kuhlmann, M., additional, Martus, P., additional, Van der Giet, M., additional, Scha ner, E., additional, Khan, I., additional, Law, Y., additional, Turgutalp, K., additional, Ozhan, O., additional, Gok Oguz, E., additional, Kiykim, A., additional, Donadio, C., additional, Hatmi, Z. N., additional, Mahdavi-Mazdeh, M., additional, Morales, E., additional, Gutierrez-Millet, V., additional, Rojas-Rivera, J., additional, Huerta, A., additional, Gutierrez, E., additional, Gutierrez-Solis, E., additional, Polanco, N., additional, Caro, J., additional, Gonza z, E., additional, Praga, M., additional, Marco Mayayo, M., additional, Valdivielso, J., additional, Marti z, M., additional, Fernaez Giraez, E., additional, Obrador, G., additional, Olvera, N., additional, Ortiz de la Pe, D., additional, Gutie ez, V., additional, Villa, A., additional, Redal-Baigorri, B., additional, Sombolos, K., additional, Tsakiris, D., additional, Boletis, J., additional, Vlahakos, D., additional, Siamopoulos, K., additional, Vargiemezis, V., additional, Nikolaidis, P., additional, Iatrou, C., additional, Dafnis, E., additional, Argyropoulos, C., additional, Xynos, K., additional, Schock-Kusch, D., additional, Shulhevich, Y., additional, Geraci, S., additional, Hesser, J., additional, Stsepankou, D., additional, Neudecker, S., additional, Koenig, S., additional, Hoecklin, F., additional, Pill, J., additional, Gretz, N., additional, Schweda, F., additional, Schreiber, A., additional, Kudo, K., additional, Konta, T., additional, Choi, S. O., additional, Kim, J. S., additional, Kim, M. K., additional, Yang, J. W., additional, Han, B. G., additional, Delanaye, P., additional, Cavalier, E., additional, Masson, I., additional, Mehdi, M., additional, Nicolas, M., additional, Lambermont, B., additional, Dubois, B., additional, Damas, P., additional, Krzesinski, J.-M., additional, Morel, J., additional, Lautrette, A., additional, Christophe, M., additional, Gagneux-Brunon, A., additional, Anne, F., additional, Fre (C)ric, L., additional, Bevc, S., additional, Ekart, R., additional, Hojs, R., additional, Gorenjak, M., additional, Puklavec, L., additional, Hashimoto, N., additional, Suzuki, A., additional, Mitsumoto, K., additional, Shimizu, M., additional, Niihata, K., additional, Kawabata, A., additional, Sakaguchi, Y., additional, Hayashi, T., additional, Shoji, T., additional, Okada, N., additional, Tsubakihara, Y., additional, Hamano, T., additional, Nakano, C., additional, Fujii, N., additional, Obi, Y., additional, Mikami, S., additional, Inoue, K., additional, Matsui, I., additional, Isaka, Y., additional, Rakugi, H., additional, Edvardsson, V., additional, Siguron, B., additional, Thorsteinsdottir, M., additional, Palsson, R., additional, Matsumoto, J., additional, Miyazaki, N., additional, Murata, I., additional, Yoshida, G., additional, Morishita, K., additional, Ushikoshi, H., additional, Nishigaki, K., additional, Ogura, S., additional, Minatoguchi, S., additional, Werneke, U., additional, Ott, M., additional, Salander-Renberg, E., additional, Taylor, D., additional, Stegmayr, B., additional, Surel, S., additional, Wenzlova, M., additional, Silva Junior, G., additional, Vieira, A. P., additional, Couto Bem, A., additional, Alves, M., additional, Torres, A., additional, Meneses, G., additional, Martins, A., additional, Liborio, A., additional, Daher, E., additional, Gluhovschi, G., additional, Modilca, M., additional, Daminescu, L., additional, Gluhovschi, C., additional, Velciov, S., additional, Petrica, L., additional, Gadalean, F., additional, Balgradean, C., additional, Schmeiser, H. H., additional, Kolesnyk, M., additional, Stepanova, N., additional, Surzhko, L., additional, Stashevska, N., additional, Filiopoulos, V., additional, Hadjiyannakos, D., additional, Arvanitis, D., additional, Panagiotopoulos, K., additional, Vlassopoulos, D., additional, Kaesler, N., additional, Schettgen, T., additional, Magdeleyns, E., additional, Brandenburg, V., additional, Vermeer, C., additional, Floege, J., additional, Kr, T., additional, Randone, O., additional, Ferraresi, M., additional, Aroasio, E., additional, Depascale, A., additional, Scognamiglio, S., additional, Consiglio, V., additional, Piccoli, G. B., additional, Jensen, L. V., additional, Lizakowski, S., additional, Rutkowski, P., additional, Tylicki, L., additional, Renke, M., additional, Sulikowska, B., additional, Donderski, R., additional, Bednarski, R., additional, Heleniak, Z., additional, Przybylska, M., additional, Manitius, J., additional, Rutkowski, B., additional, Bobrova, L., additional, Kozlovskaya, N., additional, Kanayama, K., additional, Hasegawa, M., additional, Kitagawa, F., additional, Ishii, J., additional, Yuzawa, Y., additional, Tanaka, K., additional, Sakai, K., additional, Hara, S., additional, Suzuki, Y., additional, Tanaka, Y., additional, Aikawa, A., additional, Hinoshita, F., additional, Hamano, N., additional, Sasaki, E., additional, Kato, A., additional, Katsuki, T., additional, Katsuma, A., additional, Imai, E., additional, Shibata, M., additional, Tada, M., additional, Shimbo, T., additional, Kikuchi, Y., additional, Oka, S., additional, Muramatsu, T., additional, Yanagisawa, N., additional, Fukutake, K., additional, Yamamoto, Y., additional, Ajisawa, A., additional, Tsuchiya, K., additional, Nitta, K., additional, Ando, M., additional, Liang, X., additional, Wang, P., additional, Liu, Z., additional, Zhao, Z., additional, Luyckx, V., additional, Bowker, S., additional, Miekle, A., additional, Toth, E., additional, Heguilen, R., additional, Malvar, A., additional, Hermes, R., additional, Cohen, L., additional, Muguerza, G., additional, Lococo, B., additional, Bernasconi, A., additional, Loboda, O., additional, Dudar, I., additional, Krot, V., additional, Alekseeva, V., additional, Ichinose, M., additional, Sasagawa, N., additional, Toyama, K., additional, Saito, A., additional, Kayamori, Y., additional, Kang, D., additional, Kim, H. W., additional, Yoshioka, K., additional, Hara, M., additional, Ohashi, K., additional, Maksudova, A., additional, Khalfina, T., additional, Cuoghi, A., additional, Bellei, E., additional, Caiazzo, M., additional, Bergamini, S., additional, Palladino, G., additional, Monari, E., additional, Tomasi, A., additional, Loiacono, E., additional, Camilla, R., additional, Dapr, V., additional, Morando, L., additional, Gallo, R., additional, Peruzzi, L., additional, Conrieri, M., additional, Bianciotto, M., additional, Bosetti, F. M., additional, Coppo, R., additional, DI Lullo, L., additional, Floccari, F., additional, Rivera, R., additional, Granata, A., additional, Faiola, R., additional, Feliziani, C., additional, Villani, A., additional, Malaguti, M., additional, Santoboni, A., additional, Kyriaki, K., additional, Droulias, J., additional, Bogdanova, M., additional, Rameev, V. V., additional, Simonyan, A. H., additional, Kozlovskaya, L. V., additional, Altiparmak, M. R., additional, Trabulus, S., additional, Akalin, N., additional, Yalin, A. S., additional, Esenkaya, A., additional, Yalin, S. F., additional, Serdengeae(C), K., additional, Arita, D., additional, Cunha, T., additional, Perez, J., additional, Sakata, M., additional, Arita, L., additional, Nogueira, M., additional, Jara, Z., additional, Souza, N., additional, Casarini, D., additional, Metzger, M., additional, Vallet, M., additional, Karras, A., additional, Froissart, M., additional, Stengel, B., additional, Houillier, P., additional, Paul, K., additional, Kretzschmar, D., additional, Yilmaz, A., additional, Ba hlein, B., additional, Titze, S., additional, Figulla, H.-R., additional, Wolf, G., additional, Busch, M., additional, Korotchaeva, Y., additional, Gordovskaya, N., additional, Kozlovskaya, L., additional, Ng, K. P., additional, Sharma, P., additional, Stringer, S., additional, Jesky, M., additional, Dutton, M., additional, Ferro, C., additional, Cockwell, P., additional, Moon, S. J., additional, Lee, S. C., additional, Yoon, S. Y., additional, Lee, J. E., additional, Han, S. J., additional, Anna, B., additional, Kirsch, T., additional, Svjetlana, L., additional, Joon-Keun, P., additional, Jan, B., additional, Johanna, K., additional, Haller, H., additional, Haubitz, M., additional, Smirnov, A., additional, Kayukov, I., additional, Rafrafi, N., additional, Degtereva, O., additional, Dobronravov, V., additional, Koch, M., additional, Stefan, H., additional, Dika, G., additional, Antoine, M.-H., additional, Husson, C., additional, Kos, J., additional, Milic, M., additional, Fucek, M., additional, Cvoriocec, D., additional, Bourgeade, M.-F., additional, Nortier, J. L., additional, Jelakovic, B., additional, Nawal, E. H., additional, Naoufal, M., additional, Nabila, M., additional, Fadwa, E. M., additional, Salma, E. K., additional, Nisrine, B., additional, Mohamed, Z., additional, Guislaine, M., additional, Mohamed Gharbi, B., additional, Benyounes, R., additional, Sotila, G. G., additional, Sorin, R., additional, Irina Magdalena, D., additional, Roxana, C., additional, Claudia, R., additional, Correa Barcellos, F., additional, Hallal, P. H., additional, Bohlke, M., additional, Boscolo Del Vechio, F., additional, Reges, A., additional, Santos, I., additional, Mielke, G., additional, Fortes, M., additional, Antunez, B., additional, Laganovic, M., additional, Vukovic Lela, I., additional, Karanovic, S., additional, Seric, J., additional, Premuic, V., additional, Fitrek, M., additional, Fodor, L., additional, Meljkovic Vrkic, T., additional, Bansal, V., additional, Hoppensteadt, D., additional, and Fareed, J., additional
- Published
- 2012
- Full Text
- View/download PDF
8. Diabetes - Clinical
- Author
-
Turgutalp, K., primary, Ozhan, O., additional, Akbay, E., additional, Tiftik, N., additional, Ozcan, T., additional, Yilmaz, S., additional, Kiykim, A., additional, Wu, H.-Y., additional, Peng, Y.-S., additional, Huang, J.-W., additional, Wu, K.-D., additional, Tu, Y.-K., additional, Chien, K.-L., additional, Kacso, I. M., additional, Moldovan, D., additional, Lenghel, A., additional, Rusu, C. C., additional, Gherman Caprioara, M., additional, Silva, A. P., additional, Fragoso, A., additional, Pinho, A., additional, Silva, C., additional, Santos, N., additional, Tavares, N., additional, Faisca, M., additional, Camacho, A., additional, Mesquita, F., additional, Leao, P., additional, Rato, F., additional, Oh, D.-J., additional, Kim, H.-R., additional, Kim, S.-H., additional, Okasha, K., additional, Sweilam, M., additional, Nagy, H., additional, Hassan Rizk, M., additional, Kirkpantur, A., additional, Afsar, B., additional, Chae, D.-W., additional, Chin, H. J., additional, Kim, S., additional, Fallahzadeh Abarghouei, M. K., additional, Dormanesh, B., additional, Roozbeh, J., additional, Kamali-Sarvestani, E., additional, Vessal, G., additional, Pakfetrat, M., additional, Sagheb, M. M., additional, Imasawa, T., additional, Nishimura, M., additional, Kawaguchi, T., additional, Ishibashi, R., additional, Kitamura, H., additional, Vlad, A., additional, Petrica, L., additional, Petrica, M., additional, Jianu, D. C., additional, Gluhovschi, G., additional, Ianculescu, C., additional, Negru, M., additional, Dumitrascu, V., additional, Gadalean, F., additional, Zamfir, A., additional, Popescu, C., additional, Giju, S., additional, Gluhovschi, C., additional, Velciov, S., additional, Milas, O., additional, Balgradean, C., additional, Ursoniu, S., additional, Soltysiak, J., additional, Zachwieja, J., additional, Fichna, P., additional, Lipkowska, K., additional, Skowronska, B., additional, Stankiewicz, W., additional, Stachowiak-Lewandowska, M., additional, Kluska-Jozwiak, A., additional, Afghahi, H., additional, Prasad, N., additional, Bhadauria, D., additional, Gupta, A., additional, Sharma, R. K., additional, Kaul, A., additional, Jain, M., additional, Loboda, O., additional, Dudar, I., additional, Korol, L., additional, Shifris, I., additional, Ito, K., additional, Abe, Y., additional, Ogahara, S., additional, Yasuno, T., additional, Watanabe, M., additional, Sasatomi, Y., additional, Hisano, S., additional, Nakashima, H., additional, Saito, T., additional, Nogaibayeva, A., additional, Tuganbekova, S., additional, Taubaldiyeva, Z., additional, Bekishev, B., additional, Trimova, R., additional, Topchii, I., additional, Semenovykh, P., additional, Galchiskaya, V., additional, Efimova, N., additional, Scherban, T., additional, Yasuda, F., additional, Shimizu, A., additional, MII, A., additional, Fukui, M., additional, Postorino, M., additional, Alessi, E., additional, Dal Moro, E., additional, Postorino, S., additional, Mannino, G., additional, Giandalia, A., additional, Mannino, D., additional, Pontrelli, P., additional, Conserva, F., additional, Accetturo, M., additional, Papale, M., additional, DI Palma, A. M., additional, Cordisco, G., additional, Grandaliano, G., additional, Gesualdo, L., additional, Kimoto, E., additional, Shoji, T., additional, Sonoda, M., additional, Shima, H., additional, Tsuchikura, S., additional, Mori, K., additional, Emoto, M., additional, Ishimura, E., additional, Nishizawa, Y., additional, Inaba, M., additional, Vogel, C., additional, Scholbach, T., additional, Bergner, N., additional, Lioudaki, E., additional, Stylianou, K., additional, Maragkaki, E., additional, Stratakis, S., additional, Panteri, M., additional, Choulaki, C., additional, Vardaki, E., additional, Ganotakis, E., additional, Daphnis, E., additional, Iqbal, M., additional, Ahmed, Z., additional, Mansur, M., additional, Iqbal, S., additional, Choudhury, S., additional, Nahar, N., additional, Ali, S., additional, Ahmed, T., additional, Alam, A., additional, Rahman, Z., additional, Islam, M., additional, Azad Khan, A., additional, Ogawa, A., additional, Sugiyama, H., additional, Kitagawa, M., additional, Morinaga, H., additional, Inoue, T., additional, Takiue, K., additional, Kikumoto, Y., additional, Uchida, H. A., additional, Kitamura, S., additional, Maeshima, Y., additional, Tsuchiyama, Y., additional, Makino, H., additional, Nazemian, F., additional, Jafari, M., additional, Zahed, N. O. S., additional, Javidi Dasht Bayaz, R., additional, DI Paolo, S., additional, Vocino, G., additional, DI Palma, A., additional, Federica, C., additional, Rocchetti, M. T., additional, Prajitno, C. W., additional, Ismail, G., additional, Ditoiu, A., additional, Stanciu, S., additional, Herlea, V., additional, Motoi, O., additional, Striker, G., additional, Uribarri, J., additional, Vlassara, H., additional, Gul, B., additional, Oz Gul, O., additional, Yildiz, A., additional, Eroglu, A., additional, Keni, N., additional, Ersoy, C., additional, Ersoy, A., additional, Imamoglu, S., additional, and Yurtkuran, M., additional
- Published
- 2012
- Full Text
- View/download PDF
9. Progression & risk factors CKD 1-5 (2)
- Author
-
Bouba, I., primary, Bountouri, C., additional, Dounousi, E., additional, Kiatou, V., additional, Georgiou, I., additional, Chatzidakis, S., additional, Kotzadamis, N., additional, Tsakiris, D., additional, Siamopoulos, K., additional, Dimas, G., additional, Iliadis, F., additional, Tegos, T., additional, Makedou, K., additional, Didangelos, T., additional, Pitsalidis, C., additional, Chatziapostolou, A., additional, Makedou, A., additional, Baloyannis, S., additional, Grekas, D., additional, Li, O., additional, Bobkova, I., additional, Tchebotareva, N., additional, Kozlovskaya, L., additional, Varshavskiy, V., additional, Mydlik, M., additional, Derzsiova, K., additional, Bohu , B., additional, Clapp, E., additional, Kosmadakis, G., additional, Smith, A., additional, Viana, J., additional, Shirreffs, S., additional, Maughan, R., additional, Feehally, J., additional, Bevington, A., additional, Ando, M., additional, Yanagisawa, N., additional, Hara, M., additional, Tsuchiya, K., additional, Nitta, K., additional, Chen, C.-H., additional, Wang, C.-L., additional, Huang, J.-W., additional, Hung, K.-Y., additional, Tsai, T.-J., additional, Gadalean, F., additional, Gluhovschi, G., additional, Kaycsa, A., additional, Trandafirescu, V., additional, Petrica, L., additional, Velciov, S., additional, Bozdog, G., additional, Gluhovschi, C., additional, Bob, F., additional, Solberg Eikrem, O., additional, Hope Jaeger-Hoie, E., additional, Hausken, T., additional, Svarstad, E., additional, de Goeij, M., additional, Liem, M., additional, de Jager, D., additional, Voormolen, N., additional, Sijpkens, Y., additional, Boeschoten, E., additional, Dekker, F., additional, Grootendorst, D., additional, Halbesma, N., additional, Moran, A.-M., additional, Kenny, E., additional, Ward, F., additional, Dunne, O. M., additional, Holian, J., additional, Watson, A. J., additional, Saginova, E., additional, Gallyamov, M., additional, Severova, M., additional, Surkova, O., additional, Fomin, V., additional, Topchii, I., additional, Kirienko, A., additional, Schenyavskaya, E., additional, Efimova, N., additional, Bondar, T., additional, Lesovaja, A., additional, Gama Axelsson, T., additional, Barany, P., additional, Heimburger, O., additional, Lindholm, B., additional, Stenvinkel, P., additional, Qureshi, A. R., additional, Bal, Z., additional, Erkmen Uyar, M., additional, Ahmed, N., additional, Tutal, E., additional, Sezer, S., additional, Labrador, P. J., additional, Gonzalez Castillo, P. M., additional, Silva Junior, G. B., additional, Liborio, A. B., additional, Lopes Filho, A. S., additional, Figueiredo Filho, A. C., additional, Vieira, A. P. F., additional, Couto Bem, A. X., additional, Guedes, A. L. M. O., additional, Costa, C. M. B. E., additional, Holanda de Souza, J., additional, Daher, E. F., additional, Donadio, C., additional, Kanaki, A., additional, Tognotti, D., additional, Donadio, E., additional, Reznik, E., additional, Guschina, V., additional, Volinkina, V., additional, Gendlin, G., additional, Storozhakov, G., additional, Capusa, C., additional, Stancu, S., additional, Badulescu, M., additional, Ilyes, A., additional, Anghel, C., additional, Mircescu, G., additional, Yonemoto, S., additional, Fujii, N., additional, Hamano, T., additional, Okuno, A., additional, Soda, T., additional, Yamanaka, K., additional, Hirai, T., additional, Nishimura, K., additional, Ichikawa, Y., additional, Boudville, N., additional, Kemp, A., additional, Champion de Crespigny, P., additional, Fassett, R., additional, Healy, H., additional, Mangos, G., additional, Moody, H., additional, Pedagogos, E., additional, Waugh, D., additional, Kirkland, G., additional, Kay, T., additional, Hoffman, D., additional, Abaterusso, C., additional, Branco, C., additional, Thomaseth, K., additional, Graziani, M. S., additional, Lupo, A., additional, Chaudhry, M., additional, Lok, C., additional, Kudo, K., additional, Konta, T., additional, Takasaki, S., additional, Degawa, N., additional, Kubota, I., additional, Nykula, T., additional, Moyseyenko, V., additional, Topchii, A., additional, Nanami, K., additional, Yoshiharu, T., additional, Hiroshi, Y., additional, Miyuki, M., additional, Masayuki, N., additional, Sotila, G. G., additional, Rugina, S., additional, Tuta, L., additional, Dumitru, I., additional, Cernat, R., additional, Rugina, C., additional, Kim, I. Y., additional, Lee, S. B., additional, Choi, B. K., additional, Son, J., additional, Lee, H. S., additional, Lee, N., additional, Rhee, H., additional, Song, S. H., additional, Seong, E. Y., additional, and Kwak, I. S., additional
- Published
- 2011
- Full Text
- View/download PDF
10. 105: Is There a Difference Between the Glomerular Filtration Rate (GFR) of Patients With HBV and HCV Chronic Hepatitis and Patients With C Cirrhosis?
- Author
-
Gluhovschi, C., primary, Gluhovschi, G., additional, Sporea, I., additional, Velciov, S., additional, Buzas, R., additional, Trandafirescu, V., additional, Petrica, L., additional, Bozdog, G., additional, Bob, F., additional, Gadalean, F., additional, Cioca, D., additional, and Vernic, C., additional
- Published
- 2010
- Full Text
- View/download PDF
11. PO03-MO-11 Does PPARγ-agonist rosiglitazone exert nephro- and neuroprotective effects in normoalbuminuric type 2 diabetes mellitus patients?
- Author
-
Petrica, L., primary, Petrica, M., additional, Vlad, A., additional, Gluhovschi, G., additional, Ianculescu, C., additional, Dumitrascu, V., additional, Giju, S., additional, Gluhovschi, C., additional, Bob, F., additional, Jianu, C.D., additional, Ursoniu, S., additional, Gadalean, F., additional, Velciov, S., additional, Trandafirescu, V., additional, Bozdog, G., additional, Marian, R., additional, and Muresan, C., additional
- Published
- 2009
- Full Text
- View/download PDF
12. The effect on proteinuria and urinary NAG of treatment with meloxicam in chronic glomerular disease patients – a preliminary study
- Author
-
Gluhovschi, G., primary, Velciov, S., additional, Kaycsa, A., additional, Trandafirescu, V., additional, Petrica, L., additional, Bozdog, G., additional, Gluhovschi, C., additional, Bob, F., additional, and Vernic, C., additional
- Published
- 2009
- Full Text
- View/download PDF
13. MULTIORGAN-PROTECTIVE ACTIONS OF BLOCKERS OF THE RENIN-ANGIOTENSIN SYSTEM, STATINS AND ERYTHROPOIETIN: COMMON PLEIOTROPIC EFFECTS IN RENO-, CARDIO- AND NEUROPROTECTION
- Author
-
Gluhovschi, G., primary, Gluhovschi, C., additional, Bob, F., additional, Velciov, S., additional, Trandafirescu, V., additional, Petrica, L., additional, and Bozdog, G., additional
- Published
- 2008
- Full Text
- View/download PDF
14. 67
- Author
-
Gluhovschi, C., primary, Gluhovschi, G., additional, Potencz, E., additional, Herman, D., additional, Trandafirescu, V., additional, Schiller, A., additional, Petrica, L., additional, Velciov, S., additional, Bozdog, G., additional, Bob, F., additional, Vernic, C., additional, Guset, V., additional, Muntean, C., additional, and Cioca, D., additional
- Published
- 2007
- Full Text
- View/download PDF
15. Bestimmung von N-Azetyl-b-D-Glukosaminidase (NAG) bei tubulären Läsionen während einer Nierenkolik mit und ohne assoziierte Harnwegsinfektionen (HWI)
- Author
-
Gluhovschi, G., primary, Velciov, S., additional, Kaycsa, A., additional, Trandafirescu, V., additional, Schiller, A., additional, Petrica, L., additional, Bozdog, G., additional, Gluhovschi, C., additional, and Bob, F., additional
- Published
- 2005
- Full Text
- View/download PDF
16. Die Verwendung der urinären NAG-Ausscheidung für die Bewertung der Entwicklung und Nephrotoxizität der HWI-Behandlung mit Amikacin
- Author
-
Gluhovschi, Gh., primary, Velciov, S., additional, Kaycsa, A., additional, Trandafirescu, V., additional, Schiller, A., additional, Petrica, L., additional, Bozdog, Gh., additional, Gluhovschi, C., additional, and Bob, F., additional
- Published
- 2004
- Full Text
- View/download PDF
17. BLOOD PRESSURE CIRCADIAN PROFILE IN HYPERTENSIVE AND NON HYPERTENSIVE CHRONIC RENAL FAILURE PATIENTS
- Author
-
Schiller, Ad., primary, Ivan, V., additional, Gluhovschi, Gh., additional, Petrica, L., additional, Trandafirescu, V., additional, Velciov, S., additional, Bozdog, Gh., additional, Bob, F., additional, Gluhovschi, C., additional, and Craciun, I., additional
- Published
- 2000
- Full Text
- View/download PDF
18. RETROPERITONEAL FIBROSIS WITH FAVORABLE EVOLUTION UNDER TREATMENT WITH TAMOXIFEN.
- Author
-
Gluhovschi, G., Velciov, S., Lazar, E., Potencz, E., Puscasiu, T., Trandafirescu, V., Petrica, L., Bozdog, G., Gluhovschi, C., Bob, F., Gadalean, F., and Lazar, D.
- Subjects
- *
RETROPERITONEAL fibrosis , *ATHEROSCLEROSIS , *FIBROSIS , *ESTROGEN receptors , *TAMOXIFEN , *THERAPEUTICS - Abstract
Retroperitoneal fibrosis (RPF), a disease with a severe outcome due to the complications it causes, can be associated with the processes of atherosclerosis with a massive and extensive fibrosis. In this paper we present a patient with retroperitoneal fibrosis in which we noticed estrogen receptors at the level of the periaortic fibrous tissue and we obtained a regression of this process under treatment with tamoxifen. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
19. THE GLOMERULAR FILTRATION RATE IN PATIENTS WITH BREAST CANCER TREATED BY RADIATION AND CHEMOTHERAPY FOLLOWED BY TAMOXIFEN. DOES TAMOXIFEN INFLUENCE RENAL FUNCTION IN PATIENTS WITH BREAST CANCER?
- Author
-
Gluhovschi, G., Velciov, S., Curescu, S., Nicola, T., Gluhovschi, C., Bob, F., Trandafirescu, V., Petrica, L., Bozdog, G., Tveici, M., and Vernic, C.
- Subjects
- *
BREAST cancer patients , *GLOMERULAR filtration rate , *KIDNEY physiology , *RADIOTHERAPY , *DRUG therapy , *TAMOXIFEN - Abstract
Introduction. Patients with breast cancer are treated after surgery by radiation and chemotherapy, potentially nephrotoxic. Patients with tumor estrogen-positive receptors are then treated with Tamoxifen with a possible renoprotective effect. Aim. To assess the effects of radiation and chemotherapy and of Tamoxifen on renal function in patients with breast cancer. Patients and Methods. We undertook a retrospective observational study on 76 breast cancer patients during 2002-2006. Depending on the estrogen receptor status of the tumour they were divided into group A (estrogen positive) with 50 patients, mean age: 57.64±9.34, treated with Tamoxifen and group B (estrogen negative), 26 patients, mean age: 50±9.83 who did not receive Tamoxifen. Both groups underwent surgical tumor resection, radiation and chemotherapy. The TNM status of the tumours was similar in both groups. (2/3 stages I and II and 1/3 stages III and IV). We followed up the GFR (MDRD 4) before radiation and chemotherapy and after this treatment. Thereafter, we followed up the GFR in group A at 1, 2 and 3 years of Tamoxifen and in group B at 1, 2 and 3 years of radiation and chemotherapy. Statistical analysis was performed using OpenEpi 2.3. software. Results. In group A the GFR declined not significantly after radiation and chemotherapy and at 1 year of Tamoxifen. At 2 ys of Tamoxifen, in the 18 surviving patients the GFR increased from 61.13±17.53 mL/min to 66.56±16.3 mL/min (p=0.009). At 3 y of Tamoxifen, the 12 surviving patients showed a preservation of the GFR. In group B the GFR declined from 88.14±14.63 mL/min (baseline) to 80.01±20.62 mL/min (p=0.0001) after radiation and chemotherapy. At 1 y after radiation and chemotherapy the GFR declined to 78.21±17.65 mL/min (p<0.001). At 2 y after radiation and chemotherapy in the 18 surviving patients the GFR declined to 70.94±13.39 mL/min (p<0.001 as compared to baseline). At 3 y in the 8 surviving patients the GFR declined to 61.36±9.17 mL/min (p=0.001 as compared to baseline). Conclusions. Patients undergoing treatment with Tamoxifen (group A) showed a preservation of their renal function. In patients undergoing radiation and chemotherapy alone (group B) we noticed a decline of the Glomerular Filtration Rate. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
20. 68: Do Prophylactic Antibiotics Ensure Protection in the Surgical Cure of Dental Foci in Patients with Chronic Glomerular Disease as Assessed by the Dynamics of Urinary N-Acetyl-β -D-Glucosaminidase (NAG)?
- Author
-
Gluhovschi, Gh., Velciov, S., Kaycsa, A., Gluhovschi, C., Bob, F., Trandafirescu, V., Petrica, L., Bozdog, Gh., and Vernic, C.
- Published
- 2007
- Full Text
- View/download PDF
21. 67: The Endothelial Pattern of Injury in Glomerulopathies (GP) as Assessed by the Immunohistochemical (IHC) Expression of von Willebrand Factor(VWF), CD 31 and CD 34
- Author
-
Gluhovschi, C., Gluhovschi, G., Potencz, E., Herman, D., Trandafirescu, V., Schiller, A., Petrica, L., Velciov, S., Bozdog, G., Bob, F., Vernic, C., Guset, V., Muntean, C., and Cioca, D.
- Published
- 2007
- Full Text
- View/download PDF
22. Pioglitazone delays proximal tubule dysfunction and improves cerebral vessel endothelial dysfunction in normoalbuminuric people with type 2 diabetes mellitus.
- Author
-
Petrica L, Vlad A, Petrica M, Jianu CD, Gluhovschi G, Gadalean F, Dumitrascu V, Ianculescu C, Firescu C, Giju S, Gluhovschi C, Bob F, Velciov S, Bozdog G, Milas O, Marian R, and Ursoniu S
- Abstract
AIM: The renal and cerebral protective effects of pioglitazone were assessed in normoalbuminuric patients with type 2 diabetes mellitus (DM). METHODS: A total of 68 normoalbuminuric type 2 DM patients were enrolled in a one-year open-label randomized controlled trial: 34 patients (pioglitazone-metformin) vs. 34 patients (glimepiride-metformin). All patients were assessed concerning urinary albumin: creatinine ratio (UACR), urinary alpha1-microglobulin, urinary beta2-microglobulin, plasma asymmetric dymethyl-arginine (ADMA), GFR, hsC-reactive protein, fibrinogen, HbA1c; pulsatility index, resistance index in the internal carotid artery and middle cerebral artery, intima-media thickness in the common carotid artery; cerebrovascular reactivity was evaluated through the breath-holding test. RESULTS: At 1 year there were differences between groups regarding ADMA, urinary beta2-microglobulin, urinary alpha1-microglobulin, parameters of inflammation, serum creatinine, GFR, UACR, the cerebral haemodynamic indices. Significant correlations were found between alpha 1-microglobulin-UACR (R(2)=0.143; P=0.001) and GFR (R(2)=0.081; P=0.01); beta2-microglobulin-UACR (R(2)=0.241; P=0.0001) and GFR (R(2)=0.064; P=0.036); ADMA-GFR (R(2)=0.338; P=0.0001), parameters of inflammation, HbA1c, duration of DM, cerebral indices. There were no correlations between ADMA-UACR, urinary alpha1-microglobulin and beta2-microglobulin. CONCLUSION: Proximal tubule (PT) dysfunction precedes albuminuria and is dissociated from endothelial dysfunction in patients with type 2 DM. Pioglitazone delays PT dysfunction and improves cerebral vessels endothelial dysfunction in normoalbuminuric patients with type 2 DM. Key words: proximal tubule; endothelial dysfunction, albuminuria; pioglitazone. [ABSTRACT FROM AUTHOR]
- Published
- 2011
23. Three Diseases Mediated by Different Immunopathologic Mechanisms-ANCA-Associated Vasculitis, Anti-Glomerular Basement Membrane Disease, and Immune Complex-Mediated Glomerulonephritis-A Common Clinical and Histopathologic Picture: Rapidly Progressive Crescentic Glomerulonephritis.
- Author
-
Gluhovschi C, Gadalean F, Velciov S, Nistor M, and Petrica L
- Abstract
Immune mechanisms play an important role in the pathogenesis of glomerulonephritis (GN), with autoimmunity being the main underlying pathogenetic process of both primary and secondary GN. We present three autoimmune diseases mediated by different autoimmune mechanisms: glomerulonephritis in vasculitis mediated by anti-neutrophil cytoplasmic antibodies (ANCAs), glomerulonephritis mediated by anti-glomerular basement membrane antibodies (anti-GBM antibodies), and immune complex-mediated glomerulonephritis. Some of these diseases represent a common clinical and histopathologic scenario, namely rapidly progressive crescentic glomerulonephritis. This is a severe illness requiring complex therapy, with the main role being played by therapy aimed at targeting immune mechanisms. In the absence of immune therapy, the crescents, the characteristic histopathologic lesions of this common presentation, progress toward fibrosis, which is accompanied by end-stage renal disease (ESRD). The fact that three diseases mediated by different immunopathologic mechanisms have a common clinical and histopathologic picture reveals the complexity of the relationship between immunopathologic mechanisms and their clinical expression. Whereas most glomerular diseases progress by a slow process of sclerosis and fibrosis, the glomerular diseases accompanied by glomerular crescent formation can progress, if untreated, in a couple of months into whole-nephron glomerulosclerosis and fibrosis. The outcome of different immune processes in a common clinical and histopathologic phenotype reveals the complexity of the relationship of the kidney with the immune system. The aim of this review is to present different immune processes that lead to a common clinical and histopathologic phenotype, such as rapidly progressive crescentic glomerulonephritis.
- Published
- 2023
- Full Text
- View/download PDF
24. Acute Acalculous Cholecystitis Associated with Abscesses-An Unknown Dual Pathology.
- Author
-
Gluhovschi C, Gadalean F, Velciov S, Petrica L, Duta C, Botoca M, and Cipu D
- Abstract
(1) Introduction and Aims: Little is known about the relationship between renal pathology and gallbladder pathology, although the two organs (the gallbladder and the right kidney) are in close proximity to one another. If a renal abscess disseminates, the gallbladder would be one of the secondary organs involved. As the bile provides a favorable environment for the development of pathogenic germs, it allows for the development of acute cholecystitis, even if calculi are absent, thus resulting in the development of acute acalculous cholecystitis. The aim of our study was to analyze the association between acute acalculous cholecystitis (AAC) and renal abscesses. (2) Methods: A department-wide retrospective cohort observational study including 67 patients with renal abscesses, with a mean age of 34.5+/-16.21 years and with five males and 62 females, was conducted. All of the patients were examined by an abdominal ultrasound. The lab tests included CBC with differential liver enzymes and serum bilirubin (in order to assess alterations in the liver function which can be associated with AAC) and serum creatinine (in order to assess the renal function). Blood culture and urine culture tests were also performed. (3) Results: Of the 67 patients with renal abscesses, eight (11.94%) were associated with acute cholecystitis: four cases (5.97%) of acalculous cholecystitis and four cases (5.97%) of calculous cholecystitis, two of which presented biliary sludge (acute micro-calculous cholecystitis). All four cases of acute acalculous cholecystitis presented with sepsis, and there was one case of septic shock at onset. We did not observe an impairment in renal function in the patients presenting with acute acalculous cholecystitis, and hepatic impairment was inconstant and moderate. All of the cases had a favorable outcome after a prompt initiation of intensive antibiotic therapy; both the renal abscess and the acute acalculous cholecystitis receded without further complications. (4) Conclusions: The association of acute acalculous cholecystitis with renal abscesses could be related to the possibility of germ dissemination from the infectious focus. In the case of a renal abscess, careful clinical, lab, and imaging exams of the gallbladder are recommended in order to ensure early therapeutic intervention in the event of an association with acute acalculous cholecystitis.
- Published
- 2023
- Full Text
- View/download PDF
25. Long noncoding RNAs may impact podocytes and proximal tubule function through modulating miRNAs expression in Early Diabetic Kidney Disease of Type 2 Diabetes Mellitus patients.
- Author
-
Petrica L, Hogea E, Gadalean F, Vlad A, Vlad M, Dumitrascu V, Velciov S, Gluhovschi C, Bob F, Ursoniu S, Jianu DC, Matusz P, Pusztai AM, Motoc A, Cretu OM, Radu D, Milas O, Golea-Secara A, Simulescu A, Mogos-Stefan M, Patruica M, Balint L, Ienciu S, Vlad D, and Popescu R
- Subjects
- Adult, Aged, Biomarkers metabolism, Biomarkers urine, Cross-Sectional Studies, Diabetes Mellitus, Type 2 genetics, Diabetes Mellitus, Type 2 physiopathology, Diabetes Mellitus, Type 2 urine, Diabetic Nephropathies physiopathology, Diabetic Nephropathies urine, Female, Gene Expression Regulation physiology, Humans, Male, MicroRNAs metabolism, Middle Aged, Protective Factors, RNA, Long Noncoding urine, Risk Factors, Young Adult, Diabetes Mellitus, Type 2 complications, Diabetic Nephropathies genetics, Kidney Tubules, Proximal physiopathology, Podocytes physiology, RNA, Long Noncoding metabolism
- Abstract
Aims: Long noncoding RNAs (lncRNAs) play key roles in the pathophysiology of DKD involving actions of microRNAs (miRNAs). The aims of the study were to establish the involvement of selected lncRNAs in the epigenetic mechanisms of podocyte damage and tubular injury in DKD of type 2 diabetes mellitus (DM) patients in relation to a particular miRNAs profile. Methods: A total of 136 patients with type 2 DM and 25 healthy subjects were assessed in a cross-sectional study concerning urinary albumin: creatinine ratio (UACR), eGFR, biomarkers of podocyte damage (synaptopodin, podocalyxin) and of proximal tubule (PT) dysfunction (Kidney injury molecule-1-KIM-1, N-acetyl-D-glucosaminidase-NAG), urinary lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), nuclear-enriched abundant transcript 1 (NEAT1), myocardial infarction-associated transcript (MIAT), taurine-upregulated gene 1 (TUG1), urinary miRNA21, 124, 93, 29a. Results: Multivariable regression analysis showed that urinary lncMALAT1 correlated directly with urinary synaptopodin, podocalyxin, KIM-1, NAG, miRNA21, 124, UACR, and negatively with eGFR, miRNA93, 29a (p<0.0001; R
2 =0.727); urinary lncNEAT1 correlated directly with synaptopodin, KIM-1, NAG, miRNA21, 124, and negatively with eGFR, miRNA93, 29a (p<0.0001; R2 =0.702); urinary lncMIAT correlated directly with miRNA93 and 29a, eGFR (p<0.0001; R2 =0.671) and negatively with synaptopodin, KIM-1, NAG, UACR, miRNA21, 124 (p<0.0001; R2 =0.654); urinary lncTUG1 correlated directly with eGFR, miRNA93, 29a, and negatively with synaptopodin, podocalyxin, NAG, miRNA21, 124 (p<0.0001; R2 =0.748). Conclusions: In patients with type 2 DM lncRNAs exert either deleterious or protective functions within glomeruli and PT. LncRNAs may contribute to DKD through modulating miRNAs expression and activities. This observation holds true independently of albuminuria and DKD stage., Competing Interests: Competing Interests: The authors have declared that no competing interest exists., (© The author(s).)- Published
- 2021
- Full Text
- View/download PDF
26. Urinary proteins detected using modern proteomics intervene in early type 2 diabetic kidney disease - a pilot study.
- Author
-
Golea-Secara A, Munteanu C, Sarbu M, Cretu OM, Velciov S, Vlad A, Bob F, Gadalean F, Gluhovschi C, Milas O, Simulescu A, Mogos-Stefan M, Patruica M, Petrica L, and Zamfir AD
- Subjects
- Aged, Albuminuria diagnosis, Albuminuria urine, Biomarkers urine, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 urine, Diabetic Nephropathies urine, Female, Humans, Kidney Diseases diagnosis, Kidney Diseases urine, Kidney Function Tests, Male, Middle Aged, Peptides, Pilot Projects, Proteome analysis, Proteomics methods, Diabetes Mellitus, Type 2 physiopathology, Diabetic Nephropathies diagnosis
- Abstract
Aim: An advanced proteomics platform for protein biomarker discovery in diabetic chronic kidney disease (DKD) was developed, validated and implemented. Materials & methods: Three Type 2 diabetes mellitus patients and three control subjects were enrolled. Urinary peptides were extracted, samples were analyzed on a hybrid LTQ-Orbitrap Velos Pro instrument. Raw data were searched using the SEQUEST algorithm and integrated into Proteome Discoverer platform. Results & discussion: Unique peptide sequences, resulted sequence coverage, scoring of peptide spectrum matches were reported to albuminuria and databases. Five proteins that can be associated with early DKD were found: apolipoprotein AI, neutrophil gelatinase-associated lipocalin, cytidine deaminase, S100-A8 and hemoglobin subunit delta. Conclusion: Urinary proteome analysis could be used to evaluate mechanisms of pathogenesis of DKD.
- Published
- 2020
- Full Text
- View/download PDF
27. Pro-inflammatory cytokines are associated with podocyte damage and proximal tubular dysfunction in the early stage of diabetic kidney disease in type 2 diabetes mellitus patients.
- Author
-
Milas O, Gadalean F, Vlad A, Dumitrascu V, Velciov S, Gluhovschi C, Bob F, Popescu R, Ursoniu S, Jianu DC, Matusz P, Pusztai AM, Secara A, Simulescu A, Stefan M, Patruica M, Petrica F, Vlad D, and Petrica L
- Subjects
- Aged, Albuminuria, Diabetes Mellitus, Type 2 complications, Diabetic Nephropathies etiology, Humans, Inflammation immunology, Interleukin-18 immunology, Interleukin-1alpha immunology, Interleukin-8 immunology, Middle Aged, Podocytes immunology, Cytokines immunology, Diabetes Mellitus, Type 2 immunology, Diabetic Nephropathies immunology, Diabetic Nephropathies pathology, Kidney Tubules, Proximal immunology, Kidney Tubules, Proximal pathology, Podocytes pathology
- Abstract
Aims: To evaluate if there is a link between inflammation (expressed by inflammatory cytokines) and the early stage of diabetic kidney disease (DKD), as shown by markers of podocyte damage and proximal tubular (PT) dysfunction., Methods: In this study were enrolled 117 type 2 DM patients (36-normoalbuminuria, 42-microalbuminuria, 39- macroalbuminuria), and 11 healthy subjects. Serum and urinary IL-1 alpha, IL-8, IL-18, urinary albumin:creatinine ratio (UACR), eGFR, biomarkers of podocyte damage (podocalyxin, synaptopodin, nephrin) and of PT dysfunction (KIM-1, NAG) were assessed., Results: In multivariable regression urinary Il-1 alpha correlated positively with podocalyxin and NAG (p < 0.0001, R
2 = 0.57); urinary IL-8 correlated directly with synaptopodin, NAG, nephrin, and KIM-1 (p < 0.0001, R2 = 0.67); urinary IL-18 correlated directly with synaptopodin, NAG, and nephrin (p < 0.0001, R2 = 0.59). Serum IL-1 alpha correlated positively with nephrin, synaptopodin, NAG (P < 0.0001, R2 = 0.68); serum IL-8 correlated directly with synaptopodin and NAG (p < 0.0001, R2 = 0.66); serum IL-18 correlated directly with NAG, KIM-1, and podocalyxin (p < 0.0001, R2 =0.647)., Conclusions: Pro-inflammatory interleukins are associated with podocyte injury and PT dysfunction in early DKD. These could exert a key role in the pathogenesis of early DKD, before the development of albuminuria., (Copyright © 2019 Elsevier Inc. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
28. MiRNA Expression is Associated with Clinical Variables Related to Vascular Remodeling in the Kidney and the Brain in Type 2 Diabetes Mellitus Patients.
- Author
-
Petrica L, Pusztai AM, Vlad M, Vlad A, Gadalean F, Dumitrascu V, Vlad D, Velciov S, Gluhovschi C, Bob F, Ursoniu S, Petrica M, Matusz P, Cretu O, Radu D, Milas O, Secara A, Simulescu A, Popescu R, and Jianu DC
- Subjects
- Adult, Cerebrovascular Disorders blood, Cerebrovascular Disorders etiology, Cerebrovascular Disorders urine, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 urine, Diabetic Angiopathies blood, Diabetic Angiopathies etiology, Diabetic Angiopathies urine, Diabetic Nephropathies blood, Diabetic Nephropathies etiology, Diabetic Nephropathies urine, Female, Humans, Kidney Tubules physiopathology, Male, MicroRNAs blood, MicroRNAs urine, Middle Aged, Podocytes pathology, Cerebrovascular Disorders metabolism, Diabetes Mellitus, Type 2 metabolism, Diabetic Angiopathies metabolism, Diabetic Nephropathies metabolism, MicroRNAs metabolism, Vascular Remodeling physiology
- Abstract
Background : The association of vascular remodeling in the kidney and the brain with a particular microRNAs (miRNA) profile is not well studied. Methods : Seventy-six patients with Type 2 diabetes and 11 healthy subjects were assessed concerning urine albumin: creatinine ratio (UACR), biomarkers of podocyte injury and of proximal tubule (PT) dysfunction. MiRNA were quantified in blood and urine by a real-time PCR System. Cerebrovascular ultrasound measurements were performed in the carotid and middle cerebral arteries. Results : MiRNA21 and miRNA124 correlated positively with nephrin, podocalyxin, synaptopodin, urinary N-acetyl-D-glucosaminidase (NAG), urinary kidney-injury molecule-1 (KIM-1), UACR, and negatively with eGFR; miRNA125a, 126, 146a, 192 correlated negatively with nephrin, podocalyxin, synaptopodin, urinary NAG, urinary KIM-1, UACR, and directly with eGFR. Plasma miRNA-21 and miRNA192 correlated directly with cerebral hemodynamics parameters of atherosclerosis and arteriosclerosis. MiRNA-124, 125a, 126, 146a showed negative correlations with the same parameters. Conclusions : In Type 2 diabetes patients there is an association of vascular remodeling in the brain and the kidney with a specific miRNAs pattern. Cerebrovascular changes occur even in normoalbuminuric patients, with 'high-to-normal' levels of podocyte injury and PT dysfunction biomarkers. These phenomena may be explained by the variability of miRNA expression within the two organs in early DKD.
- Published
- 2020
- Full Text
- View/download PDF
29. Interleukins and miRNAs intervene in the early stages of diabetic kidney disease in Type 2 diabetes mellitus patients.
- Author
-
Petrica L, Milas O, Vlad M, Vlad A, Gadalean F, Dumitrascu V, Velciov S, Gluhovschi C, Bob F, Ursoniu S, Jianu DC, Matusz P, Pusztai AM, Cretu O, Radu D, Secara A, Simulescu A, Stefan M, Popescu R, and Vlad D
- Subjects
- Adult, Aged, Diabetic Nephropathies etiology, Diabetic Nephropathies genetics, Female, Humans, Interleukin-18 blood, Interleukin-18 urine, Male, MicroRNAs genetics, Middle Aged, Young Adult, Diabetes Mellitus, Type 2 complications, Diabetic Nephropathies blood, Diabetic Nephropathies urine, Interleukins blood, Interleukins urine, MicroRNAs blood, MicroRNAs urine
- Abstract
Aim: The involvement of proinflammatory interleukins (IL) in diabetic kidney disease of Type 2 diabetes mellitus (DM) patients was studied in relation to a particular miRNA profile. Materials & methods: A total of 117 patients with Type 2 DM and 11 controls were enrolled in a case series study. Serum and urinary ILs and miRNAs were assessed. Results: IL-1α correlated with miRNA21, 124, estimated glomerular filtration rate (eGFR) and negatively with miRNA125a and 192; IL-8 with miRNA21, 124, eGFR and negatively with miRNA125a, 126 and 146a; IL-18 with miRNA21, 124 and negatively with miRNA146a, 192, eGFR. Conclusion: There is an association between specific serum and urinary ILs and serum and urinary miRNAs profiles in the inflammatory response in Type 2 DM patients with diabetic kidney disease.
- Published
- 2019
- Full Text
- View/download PDF
30. Deregulated profiles of urinary microRNAs may explain podocyte injury and proximal tubule dysfunction in normoalbuminuric patients with type 2 diabetes mellitus.
- Author
-
Milas O, Gadalean F, Vlad A, Dumitrascu V, Gluhovschi C, Gluhovschi G, Velciov S, Popescu R, Bob F, Matusz P, Pusztai AM, Cretu OM, Secara A, Simulescu A, Ursoniu S, Vlad D, and Petrica L
- Subjects
- Aged, Albuminuria genetics, Albuminuria physiopathology, Albuminuria urine, Diabetes Mellitus, Type 2 genetics, Diabetes Mellitus, Type 2 physiopathology, Diabetes Mellitus, Type 2 urine, Humans, Kidney Tubules, Proximal pathology, Middle Aged, Multivariate Analysis, Podocytes metabolism, Albuminuria complications, Diabetes Mellitus, Type 2 complications, Gene Expression Profiling, Kidney Tubules, Proximal physiopathology, MicroRNAs genetics, MicroRNAs urine, Podocytes pathology
- Abstract
MicroRNAs (miRNAs) are short non-coding RNA species that are important post-transcriptional regulators of gene expression. The aim of the study was to establish a potential explanation of podocyte damage and proximal tubule (PT) dysfunction induced by deregulated miRNAs expression in the course of type 2 diabetes mellitus (DM). A total of 68 patients with type 2 DM and 11 healthy subjects were enrolled in a cross-sectional study and assessed concerning urinary albumin:creatinine ratio (UACR), urinary N -acetyl-β-D-glucosamininidase (NAG), urinary kidney injury molecule-1, urinary nephrin, podocalyxin, synaptopodin, estimated glomerular filtration rate (eGFR), urinary miRNA21, miRNA124, and miRNA192. In univariable regression analysis, miRNA21, miRNA124, and miRNA192 correlated with urinary nephrin, synaptopodin, podocalyxin, NAG, KIM-1, UACR, and eGFR. Multivariable regression analysis yielded models in which miRNA192 correlated with synaptopodin, uNAG, and eGFR (R
2 =0.902; P<0.0001), miRNA124 correlated with synaptopodin, uNAG, UACR, and eGFR (R2 =0.881; P<0.0001), whereas miRNA21 correlated with podocalyxin, uNAG, UACR, and eGFR (R2 =0.882; P<0.0001). Urinary miRNA192 expression was downregulated, while urinary miRNA21 and miRNA124 expressions were upregulated. In patients with type 2 DM, there is an association between podocyte injury and PT dysfunction, and miRNA excretion, even in the normoalbuminuria stage. This observation documents a potential role of the urinary profiles of miRNA21, miRNA124, and miRNA192 in early DN. Despite their variability across the segments of the nephron, urinary miRNAs may be considered as a reliable tool for the identification of novel biomarkers in order to characterize the genetic pattern of podocyte damage and PT dysfunction in early DN of type 2 DM., Competing Interests: Competing interests: None declared., (© American Federation for Medical Research (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.)- Published
- 2018
- Full Text
- View/download PDF
31. Therapy with atorvastatin versus rosuvastatin reduces urinary podocytes, podocyte-associated molecules, and proximal tubule dysfunction biomarkers in patients with type 2 diabetes mellitus: a pilot study.
- Author
-
Vlad A, Vlad M, Petrica L, Ursoniu S, Gadalean F, Popescu R, Vlad D, Dumitrascu V, Gluhovschi G, Gluhovschi C, Velciov S, Bob F, Matusz P, Secara A, Simulescu A, and Jianu DC
- Subjects
- Aged, Albuminuria complications, Biomarkers, Female, Glomerular Filtration Rate, Glycation End Products, Advanced urine, Humans, Kidney Tubules, Proximal physiopathology, Male, Membrane Proteins urine, Middle Aged, Pilot Projects, Prospective Studies, Vascular Endothelial Growth Factor A urine, Atorvastatin therapeutic use, Diabetes Mellitus, Type 2 complications, Diabetic Nephropathies drug therapy, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Podocytes drug effects, Rosuvastatin Calcium therapeutic use
- Abstract
Background: Diabetic nephropathy is a severe complication of Type 2 diabetes. Tubular lesions may play an important role in its early stages. The aim of our study was to determine if atorvastatin protects the podocytes and the proximal tubule in patients with Type 2 diabetes., Methods: A total of 63 patients with Type 2 diabetes completed this 6-months prospective pilot study. They were randomized to continue rosuvastatin therapy (control group) or to be administered an equipotent dose of atorvastatin (intervention group), and were assessed regarding urinary podocytes, podocyte-associated molecules, and biomarkers of proximal tubule dysfunction., Results: The patients from the intervention group presented a significant reduction in podocyturia (from 7.0 to 4.0 cells/ml, p < .05), urinary nephrin (from 1.7 to 1.3 mg/g, p < .001), urinary vascular endothelial growth factor (from 262.8 to 256.9, p < .01), urinary alpha
1 -microglobulin (from 10.0 to 8.3 mg/g, p < .01), urinary kidney injury molecule-1 (from 139.5 to 136.3 ng/g, p < .001), and urinary advanced glycation end-products (from 112.6 to 101.3 pg/ml, p < .001). Podocyturia correlated directly with the podocyte damage biomarkers, proximal tubule dysfunction biomarkers, albumin to creatinine ratio, and advanced glycation end-products, and inversely with the glomerular filtration rate., Conclusions: In patients with Type 2 diabetes, atorvastatin exerts favorable effects on the kidney. There is a correlation between the evolution of the podocytes and of the proximal tubule biomarkers, supporting the hypothesis that the glomerular changes parallel proximal tubule dysfunction in the early stages of diabetic nephropathy.- Published
- 2017
- Full Text
- View/download PDF
32. The impact of acute kidney injury on in-hospital mortality in acute ischemic stroke patients undergoing intravenous thrombolysis.
- Author
-
Gadalean F, Simu M, Parv F, Vorovenci R, Tudor R, Schiller A, Timar R, Petrica L, Velciov S, Gluhovschi C, Bob F, Mihaescu A, Timar B, Spasovski G, and Ivan V
- Subjects
- Acute Kidney Injury complications, Acute Kidney Injury drug therapy, Acute Kidney Injury urine, Administration, Intravenous, Aged, Biomarkers urine, Brain Ischemia complications, Brain Ischemia drug therapy, Brain Ischemia urine, Female, Glomerular Filtration Rate, Humans, Male, Middle Aged, Patient Discharge statistics & numerical data, Prospective Studies, Stroke complications, Stroke drug therapy, Stroke urine, Survival Analysis, Thrombolytic Therapy methods, Treatment Outcome, Uric Acid urine, Acute Kidney Injury mortality, Brain Ischemia mortality, Fibrinolytic Agents therapeutic use, Hospital Mortality trends, Stroke mortality, Tissue Plasminogen Activator therapeutic use
- Abstract
Introduction: Acute kidney injury (AKI) increases the risk of death in acute ischemic stroke (AIS) patients. Intravenous thrombolytic therapy (iv. rt-PA) seems to be the most effective treatment for AIS patients. The effects of AKI on iv. rt-PA treated AIS cases is less studied. Our paper addresses this issue., Methods: 45 consecutive stroke patients treated with iv. rt-PA (median age = 64 years; 29 male) and 59 age and sex matched controls not eligible for iv. rt-PA have been enrolled in our study. Subjects were followed-up until hospital release or death (median follow up time = 12 days)., Results: The prevalence of AKI did not differ between iv. rt-PA treated patients and controls (35.5% vs. 33.89%). In both groups, AKI was associated with increased in-hospital mortality: 50.0% vs. 3.4% p<0.0001 (in the rt-PA treated), and 45% vs. 30.7% (in controls). AKI iv. rt-PA treated patients had a significantly higher risk of in hospital mortality as compared to the no-AKI iv. rt-PA treated (HR = 15.2 (95%CI [1.87 to 124.24]; P = 0.011). In a Cox-multivariate model, the presence of AKI after iv. rt-PA remained a significant factor (HR = 8.354; p = 0.041) influencing the in-hospital mortality even after correction for other confounding factors. The independent predictors for AKI were: decreased eGFR baseline and elevated serum levels of uric acid at admission, (the model explained 60.2% of the AKI development)., Conclusions: The risk of AKI was increased in AIS patients. Thrombolysis itself did not increase the risk of AKI. In the iv. rt-PA patients, as compared to non-AKI, those which developed AKI had a higher rate of in-hospital mortality. The baseline eGFR and the serum uric acid at admission were independent predictors for AKI development in the iv. rt-PA treated AIS patients.
- Published
- 2017
- Full Text
- View/download PDF
33. Podocyturia parallels proximal tubule dysfunction in type 2 diabetes mellitus patients independently of albuminuria and renal function decline: A cross-sectional study.
- Author
-
Petrica L, Vlad M, Vlad A, Gluhovschi G, Gadalean F, Dumitrascu V, Popescu R, Gluhovschi C, Matusz P, Velciov S, Bob F, Ursoniu S, and Vlad D
- Subjects
- Case-Control Studies, Cells, Cultured, Cross-Sectional Studies, Diabetes Mellitus, Type 2 pathology, Diabetic Nephropathies complications, Diabetic Nephropathies pathology, Diabetic Nephropathies physiopathology, Diabetic Nephropathies urine, Female, Glomerular Filtration Rate, Humans, Kidney pathology, Kidney physiopathology, Kidney Function Tests, Kidney Tubules, Proximal pathology, Male, Middle Aged, Urinalysis methods, Albuminuria complications, Albuminuria pathology, Albuminuria physiopathology, Albuminuria urine, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 physiopathology, Diabetes Mellitus, Type 2 urine, Kidney Tubules, Proximal physiopathology, Podocytes pathology, Urine cytology
- Abstract
Aims: Detection of podocytes in the urine of patients with type 2 diabetes may indicate severe injury to the podocytes. In the course of type 2 diabetes the proximal tubule is involved in urinary albumin processing. We studied the significance of podocyturia in relation with proximal tubule dysfunction in type 2 diabetes., Methods: A total of 86 patients with type 2 diabetes (34-normoalbuminuria; 30-microalbuminuria; 22-macroalbuminuria) and 28 healthy subjects were enrolled in the study and assessed concerning urinary podocytes, podocyte-associated molecules, and biomarkers of proximal tubule dysfunction. Urinary podocytes were examined in cell cultures by utilizing monoclonal antibodies against podocalyxin and synaptopodin., Results: Podocytes were detected in the urine of 10% of the healthy controls, 24% of the normoalbuminuric, 40% of the microalbuminuric, and 82% of the macroalbuminuric patients. In multivariate logistic regression analysis, urinary podocytes correlated with urinary albumin:creatinine ratio (p=0.006), urinary nephrin/creat (p=0.001), urinary vascular endothelial growth factor/creat (p=0.001), urinary kidney injury molecule-1/creat (p=0.003), cystatin C (p=0.001), urinary advanced glycation end-products (p=0.002), eGFR (p=0.001)., Conclusions: In patients with type 2 diabetes podocyturia parallels proximal tubule dysfunction independently of albuminuria and renal function decline. Advanced glycation end-products may impact the podocytes and the proximal tubule., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
34. Urinary podocyte-associated mRNA levels correlate with proximal tubule dysfunction in early diabetic nephropathy of type 2 diabetes mellitus.
- Author
-
Petrica L, Ursoniu S, Gadalean F, Vlad A, Gluhovschi G, Dumitrascu V, Vlad D, Gluhovschi C, Velciov S, Bob F, Matusz P, Milas O, Secara A, Simulescu A, and Popescu R
- Abstract
Aim: The study assessed mRNA expression of podocyte-associated molecules in urinary sediments of patients with type 2 diabetes mellitus (DM) in relation to urinary podocytes, biomarkers of podocyte injury and of proximal tubule (PT) dysfunction., Methods: A total of 76 patients with type 2 DM and 20 healthy subjects were enrolled in a cross-sectional study, and assessed concerning urinary podocytes, urinary mRNA of podocyte-associated genes, urinary biomarkers of podocyte damage and of PT dysfunction., Results: We found significant differences between urinary mRNA of podocyte-associated molecules in relation with albuminuria stage. In multivariable regression analysis, urinary mRNA of nephrin, podocin, alpha-actinin-4, CD2-associated protein, glomerular epithelial protein 1 (GLEPP1), ADAM 10, and NFκB correlated directly with urinary podocytes, albuminuria, urinary alpha
1 -microglobulin, urinary kidney-injury molecule-1, nephrinuria, urinary vascular endothelial growth factor, urinary advanced glycation end-products (AGE), and indirectly with eGFR (p < 0.0001, R2 = 0.808; p < 0.0001, R2 = 0.825; p < 0.0001, R2 = 0.805; p < 0.0001, R2 = 0.663; p < 0.0001, R2 = 0.726; p < 0.0001, R2 = 0.720; p < 0.0001, R2 = 0.724)., Conclusions: In patients with type 2 DM there is an association between urinary mRNA of podocyte-associated molecules, biomarkers of podocyte damage, and of PT dysfunction. GLEPP1, ADAM10, and NFκB may be considered additional candidate molecules indicative of early diabetic nephropathy. AGE could be involved in this association.- Published
- 2017
- Full Text
- View/download PDF
35. Renal function is similar in solitary kidneys from patients with and without diabetes.
- Author
-
Gluhovschi C, Gluhovschi G, Gadalean F, Velciov S, Petrica L, Timar B, Kaycsa A, and Timar R
- Subjects
- Diabetic Nephropathies complications, Female, Humans, Kidney Function Tests, Male, Middle Aged, Solitary Kidney complications, Diabetes Mellitus physiopathology, Diabetic Nephropathies physiopathology, Kidney physiopathology, Solitary Kidney physiopathology
- Abstract
Objectives: Due to the shortage of living kidney donors and the current diabetes mellitus (DM) pandemic, studying the association of solitary kidney (SK) with DM is of paramount importance. Our aim was to assess the significance of the association between SK and DM., Materials and Methods: Eighty-four patients with SK and DM (group A), with a mean age of 62.46±12.72 years, of whom 36 were males and 48 were females, were enrolled in the study. The control group (group B) comprised 84 SK patients without DM of similar age and duration of existence of a SK. Mean age: 61.58±8.22 years, 23 males and 61 females. Serum creatinine, GFR (CKD-EPI), glycaemia, cholesterol, triglycerides, uric acid, proteinuria/24h, systolic blood pressure (SBP), diastolic blood pressure (DBP) and BMI were assessed., Results: The group of patients with SK and DM (group A) had a higher BMI (p=0.0007), higher metabolic abnormalities (higher glycaemia [p<0.001], triglycerides [p=0.0004], uric acid [p=0.019] and proteinuria/24h [p=0.006]). The study group also had a higher prevalence of hypertension (p=0.003) and coronary artery disease (p=0.031)., Conclusions: We found a higher value of proteinuria in the study group, significant metabolic abnormalities, as well as a higher prevalence of hypertension and coronary artery disease. However, no differences with respect to GFR were found, which could have significant implications for transplantation., (Copyright © 2016 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
36. Is ciprofloxacin safe in patients with solitary kidney and upper urinary tract infection?
- Author
-
Gluhovschi G, Gadalean F, Gluhovschi C, Velciov S, Petrica L, Bob F, Bozdog G, and Kaycsa A
- Subjects
- Acetylglucosaminidase urine, Alpha-Globulins urine, Ciprofloxacin pharmacology, Female, Glomerular Filtration Rate drug effects, Humans, Kidney drug effects, Kidney pathology, Kidney physiopathology, Male, Middle Aged, Urinary Tract Infections pathology, Urinary Tract Infections physiopathology, Urinary Tract Infections urine, Ciprofloxacin therapeutic use, Kidney abnormalities, Urinary Tract Infections drug therapy
- Abstract
The solitary kidney (SK) undergoes adaptive phenomena of hyperfunction and hyperfiltration. These secondary adaptive phenomena can make it more vulnerable to potentially nephrotoxic therapies. Adverse reactions of the kidneys to ciprofloxacin are rare, but sometimes severe. Therefore, our study sought to assess the reactions to ciprofloxacin of patients with solitary kidney (SK) and urinary tract infection (UTI) by means of urinary biomarkers. We studied 19 patients with SK and urinary tract infection (UTI) who had been administered a 7-day treatment with intravenous ciprofloxacin. Urinary N-acetyl-beta-d-glucosaminidase, alpha 1-microglobulin, and estimated glomerular filtration rate (eGFR) of these patients were measured at the initiation and at the end of treatment. In 47.37% patients NAG diminished under ciprofloxacin treatment. This observation has the significance of favourable evolution of the tubulointerstitial lesions caused by UTI and lack of nephrotoxic effects; 52.63% cases presented an increase of urinary NAG, a fact that suggests a nephrotoxic effect of ciprofloxacin. The evolution of urinary alpha 1-microglobulin was similar to that one of urinary NAG. Only one of three cases with chronic kidney disease (CKD) stage 5 presented acute kidney injury, associated with increase in the tubular markers. In spite of the high variability of the urinary biomarkers, UTI evolved favourably in these cases; eGFR increased in 16 out of 19 patients, a fact which is indicative of a good outcome of renal function, even in patients with elevated levels of the tubular damage biomarkers. This observation supports the hypothesis that eGFR may be dissociated from the biomarkers which assess tubular injury. In SK patients the occurrence of AKI is not frequent, although the urinary biomarkers rise in some patients treated with ciprofloxacin. This is related not only to the nephrotoxic effect of the drug, but probably to the association of other factors (allergy, individual susceptibility). In SK patients, renal tubular biomarkers, especially NAG, allow monitoring of tubular injury and impose caution in prescribing ciprofloxacin treatment, mainly to patients at risk. Ciprofloxacin is relatively safe regarding its nephrotoxicity, while caution is required in vulnerable patients., (Copyright © 2016 Elsevier Masson SAS. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
37. Urinary enzymatic markers (N-acetyl-beta-D-glucosaminidase) in assessing the tubulointerstitial compartment in chronic glomerulonephritis related to odontogenic foci.
- Author
-
Velciov S, Gluhovschi G, Timar R, Gluhovschi C, Petrica L, Bob F, Bozdog G, Pricop M, Gluhovschi A, Cornianu M, Potencz E, Timar B, and Kaycsa A
- Subjects
- Adult, Biomarkers urine, Female, Focal Infection, Dental etiology, Glomerulonephritis complications, Humans, Kidney Tubules enzymology, Male, Reproducibility of Results, Sensitivity and Specificity, Acetylglucosaminidase urine, Focal Infection, Dental diagnosis, Focal Infection, Dental urine, Glomerulonephritis diagnosis, Glomerulonephritis urine
- Abstract
Chronic glomerulonephritis is related to focus infection. Odontogenic foci are frequently involved in glomerulonephritis. The relationship with the odontogenic focus infection can be demonstrated by the occurrence or aggravation of the symptoms of glomerulonephritis: proteinuria, haematuria, high blood pressure and oedema. Glomerular impairment in glomerulonephritis occurs together with inflammatory alterations of the tubulointerstitial compartment that can play an important part in the evolution of the disease. Tubular urinary markers can indicate the activation of this compartment during an infection of a focus, an odontogenic focus in our study.The paper aims at demonstrating the relationship between the odontogenic focus infection and tubulointerstitial lesions, assessed by a tubular urinary marker, N-acetyl beta-D glucosaminidase (NAG).We investigated the urinary N-acetyl beta-D glucosaminidase of 20 patients with chronic glomerulonephritis who presented odontogenic focus infections, comparing them with patients with chronic glomerulonephritis without odontogenic foci and of 20 controls, clinically healthy persons.Chronic glomerulonephritis patients with odontogenic focus infection presented clearly increased values as compared to clinically healthy control persons of urinary N-acetyl beta-D glucosaminidase.These patients underwent surgical intervention on the odontogenic focus under antibacterial prophylactic treatment. In 75% cases, the values of N-acetyl beta-D glucosaminidase diminished, indicating the favourable effect of the treatment of the odontogenic focus on the tubulointerstitial compartment in patients with chronic glomerulonephritis. In 25% cases this therapeutic treatment was associated with an increase of the values of urinary N-acetyl beta-D glucosaminidase, expressing its unfavourable effect on chronic glomerulonephritis.Urinary N-acetyl beta-D glucosaminidase indicated an etiopathogenetic relationship between the odontogenic focus and the tubulointerstitial compartment in chronic glomerulonephritis.
- Published
- 2016
- Full Text
- View/download PDF
38. Urinary Biomarkers in the Assessment of Early Diabetic Nephropathy.
- Author
-
Gluhovschi C, Gluhovschi G, Petrica L, Timar R, Velciov S, Ionita I, Kaycsa A, and Timar B
- Subjects
- Early Diagnosis, Humans, Albuminuria urine, Biomarkers urine, Diabetic Nephropathies urine
- Abstract
Diabetic nephropathy (DN) is a frequent and severe complication of diabetes mellitus (DM). Its diagnosis in incipient stages may allow prompt interventions and an improved prognosis. Towards this aim, biomarkers for detecting early DN can be used. Microalbuminuria has been proven a remarkably useful biomarker, being used for diagnosis of DN, for assessing its associated condition-mainly cardiovascular ones-and for monitoring its progression. New researches are pointing that some of these biomarkers (i.e., glomerular, tubular, inflammation markers, and biomarkers of oxidative stress) precede albuminuria in some patients. However, their usefulness is widely debated in the literature and has not yet led to the validation of a new "gold standard" biomarker for the early diagnosis of DN. Currently, microalbuminuria is an important biomarker for both glomerular and tubular injury. Other glomerular biomarkers (transferrin and ceruloplasmin) are under evaluation. Tubular biomarkers in DN seem to be of a paramount importance in the early diagnosis of DN since tubular lesions occur early. Additionally, biomarkers of inflammation, oxidative stress, podocyte biomarkers, and vascular biomarkers have been employed for assessing early DN. The purpose of this review is to provide an overview of the current biomarkers used for the diagnosis of early DN.
- Published
- 2016
- Full Text
- View/download PDF
39. Glycated peptides are associated with the variability of endothelial dysfunction in the cerebral vessels and the kidney in type 2 diabetes mellitus patients: a cross-sectional study.
- Author
-
Petrica L, Vlad A, Gluhovschi G, Gadalean F, Dumitrascu V, Vlad D, Popescu R, Velciov S, Gluhovschi C, Bob F, Ursoniu S, Petrica M, and Jianu DC
- Subjects
- Aged, Albuminuria etiology, Arginine analogs & derivatives, Arginine blood, Biomarkers blood, Biomarkers urine, Breath Holding, Cohort Studies, Cross-Sectional Studies, Diabetic Angiopathies blood, Diabetic Angiopathies physiopathology, Diabetic Angiopathies urine, Diabetic Nephropathies blood, Diabetic Nephropathies physiopathology, Diabetic Nephropathies urine, Endothelium, Vascular metabolism, Female, Glomerular Filtration Rate, Glycation End Products, Advanced blood, Glycation End Products, Advanced urine, Humans, Kidney blood supply, Kidney metabolism, Male, Middle Aged, Outpatient Clinics, Hospital, Romania, Severity of Illness Index, Vasculitis, Central Nervous System metabolism, Vasculitis, Central Nervous System physiopathology, Vasculitis, Central Nervous System urine, Diabetes Mellitus, Type 2 complications, Diabetic Angiopathies metabolism, Diabetic Nephropathies metabolism, Endothelium, Vascular physiopathology, Glycation End Products, Advanced metabolism, Kidney physiopathology, Vasculitis, Central Nervous System complications
- Abstract
Background: Diabetic atherosclerosis and microangiopathy parallel diabetic nephropathy. The aim of our study was to evaluate the pattern of endothelial dysfunction in two vascular territories, the kidney and the brain, both affected by diabetic vasculopathic complications. The endothelial variability was evaluated in relation to advanced glycation end-products modified peptides., Methods: Seventy patients with type 2 diabetes mellitus and 11 healthy subjects were assessed concerning urine albumin: creatinine ratio, plasma and urinary advanced glycation end-products, plasma asymmetric dimethyl-arginine, serum cystatin C, intima-media thickness in the common carotid arteries, the pulsatility index, the resistance index in the internal carotid arteries and the middle cerebral arteries, the cerebrovascular reactivity through the breath-holding test., Results: The breath-holding index correlated with asymmetric dimethyl-arginine (R²=0.151; p<0.001), plasma advanced glycation end-products (R²=0.173; p<0.001), C-reactive protein (R²=0.587; p<0.001), duration of diabetes mellitus (R²=0.146; p=0.001), cystatin C (R²=0.220; p<0.001), estimated glomerular filtration rate (R²=0.237; p=0.001). Urine albumin: creatinine ratio correlated with urinary advanced glycation end-products (R²=0.257; p<0.001), but not with asymmetric dimethyl-arginine (R²=0.029; p=0.147)., Conclusions: In type 2 diabetic patients endothelial dysfunction in the cerebral vessels appears to be dissociated from glomerular endothelial dysfunction in early diabetic nephropathy. Advanced glycation end-products could impact both the cerebral vessels and the glomerular endothelium., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
40. Familial versus environmental factors in Balkan endemic nephropathy in Mehedinti county, Romania, by means of albuminuria and tubular biomarkers: preliminary study.
- Author
-
Gluhovschi G, Modilca M, Velciov S, Gluhovschi C, Petrica L, Vernic C, and Kaycsa A
- Subjects
- Adult, Biomarkers metabolism, Environmental Health methods, Environmental Health statistics & numerical data, Family Health statistics & numerical data, Female, Glomerular Filtration Rate, Humans, Male, Middle Aged, Romania epidemiology, Acetylglucosaminidase metabolism, Albuminuria diagnosis, Albuminuria etiology, Alpha-Globulins metabolism, Balkan Nephropathy complications, Balkan Nephropathy diagnosis, Balkan Nephropathy epidemiology, Balkan Nephropathy metabolism, Balkan Nephropathy physiopathology, Kidney Failure, Chronic diagnosis, Kidney Failure, Chronic epidemiology, Kidney Failure, Chronic etiology
- Abstract
Introduction and Aims: Balkan endemic nephropathy (BEN), a regional tubulointerstitial kidney disease encountered in South-Eastern Europe, with still undefined etiology and inexorable evolution towards end stage renal disease, raises the question of the relative contribution of family and environmental factors in its etiology. In order to evaluate the intervention of these factors, markers of tubular injury have been assessed, this lesion being considered an early renal involvement in BEN., Methods: The paper studies relatives of BEN patients currently included in dialysis programmes (for involvement of the family factor) and their neighbors (for involvement of environmental factors) and analyzes them with regard to tubular injury by means of tubular biomarkers (N-acetyl-beta-d-glucosaminidase-NAG and alpha-1-microglobulin), and albuminuria. At the same time, glomerular filtration rate (GFR) (CKD-EPI) was measured. It is considered that, in order to acquire the disease, one should have lived for 20 years in the BEN area. The relatives have been classified according to this criterion., Results: More evident tubular injury was found in the neighbors of BEN patients living for more than 20 years in the endemic area, which argues in favor of environmental factors. Higher levels of urinary alpha-1-microglobulin and albumin in relatives of BEN patients who had been living for more than 20 years in the area than in relatives with a residence under 20 years, plead for the same hypothesis. GFR was lower in persons who had been living for more than 20 years in the BEN area (neighbors and relatives)., Conclusions: Environmental factors could be more important in BEN than family factors.
- Published
- 2015
- Full Text
- View/download PDF
41. Glycated peptides are associated with proximal tubule dysfunction in type 2 diabetes mellitus.
- Author
-
Petrica L, Vlad A, Gluhovschi G, Zamfir A, Popescu C, Gadalean F, Dumitrascu V, Vlad D, Popescu R, Velciov S, Gluhovschi C, Bob F, Milas O, and Ursoniu S
- Abstract
Background: Advanced glycation end-products have been involved in the pathogenesis of proximal tubule dysfunction which characterizes diabetic tubulopathy., Methods: A total of 76 Type 2 diabetes mellitus patients and 28 healthy controls were evaluated concerning a potential association of glycated peptides with proximal tubule dysfunction by assessing urine albumin:creatinine ratio, urinary alpha1-microglobulin, urinary neutrophil gelatinase-associated lipocalin, plasma and urinary advanced glycation end-products, plasma asymmetric dimethyl-arginine, serum cystatin C. Fully automated chip-nanoelectrospray ionization and high-capacity ion trap multistage mass spectrometry characterized the urinary proteomic profile., Results: The urinary glycated proteins displayed a molecular weight of 15,121.4 Da in normoalbuminuric patients and of 30,180.4 Da in microalbuminuric patients. Urinary alpha1-microglobulin and neutrophil gelatinase-associated lipocalin correlated with urinary advanced glycation end-products (R(2)=0.586; R(2)=0.415), urine albumin: creatinine ratio (R(2)=0.292; R(2)=0.116), estimated glomerular filtration rate (R(2)=0.172; R(2)=0.135), serum cystatin C (R(2)=0.146; R(2)=0.129), but not with asymmetric dimethyl-arginine. In multivariable regression analysis models, the correlations for urinary alpha1-microglobulin and neutrophil gelatinase-associated lipocalin remained significant with urine albumin: creatinine ratio, urinary advanced glycation end-products, estimated glomerular filtration rate (P<0.0001, R(2)=0.674; P<0.0001, R(2)=0.551; P<0.0001, R(2)=0.482)., Conclusions: In patients with Type 2 diabetes mellitus urinary glycated peptides are associated with proximal tubule dysfunction. The proteomic patterns of urinary glycated peptides could differentiate normo- from microalbuminuric patients and may explain a potential relation between the size and the glycation status of glycated peptides, and the extent of proximal tubule dysfunction. The lack of correlation between parameters of endothelial dysfunction and proximal tubule dysfunction cannot exclude glomerular involvement in early diabetic nephropathy.
- Published
- 2015
42. Pregnancy Associated with Systemic Lupus Erythematosus: Immune Tolerance in Pregnancy and Its Deficiency in Systemic Lupus Erythematosus--An Immunological Dilemma.
- Author
-
Gluhovschi C, Gluhovschi G, Petrica L, Velciov S, and Gluhovschi A
- Subjects
- Animals, Female, Humans, Immune System immunology, Pregnancy, T-Lymphocytes, Regulatory immunology, Immune Tolerance immunology, Lupus Erythematosus, Systemic immunology, Pregnancy Complications immunology
- Abstract
Pregnancy is a physiological condition that requires immune tolerance to the product of conception. Systemic lupus erythematosus (SLE) is a disease with well-represented immune mechanisms that disturb immune tolerance. The association of pregnancy with systemic lupus erythematosus creates a particular immune environment in which the immune tolerance specific of pregnancy is required to coexist with alterations of the immune system caused by SLE. The main role is played by T regulatory (Treg) cells, which attempt to regulate and adapt the immune system of the mother to the new conditions of pregnancy. Other components of the immune system also participate to maintain maternal-fetal immune tolerance. If the immune system of pregnant women with SLE is not able to maintain maternal immune tolerance to the fetus, pregnancy complications (miscarriage, fetal hypotrophy, and preterm birth) or maternal complications (preeclampsia or activation of SLE, especially in conditions of lupus nephritis) may occur. In certain situations this can be responsible for neonatal lupus. At the same time, it must be noted that during pregnancy, the immune system is able to achieve immune tolerance while maintaining the anti-infectious immune capacity of the mother. Immunological monitoring of pregnancy during SLE, as well as of the mother's disease, is required. It is important to understand immune tolerance to grafts in transplant pathology.
- Published
- 2015
- Full Text
- View/download PDF
43. Chronic Kidney Disease--Chronic Liver Disease. An Immunologic Cross-talk.
- Author
-
Gluhovschi G, Petrică L, Sporea I, Timar R, Curescu M, Velciov S, and Gluhovschi C
- Subjects
- Chronic Disease, Humans, Liver Diseases therapy, Renal Insufficiency, Chronic therapy, Liver Diseases complications, Liver Diseases immunology, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic immunology
- Abstract
The relationship between the kidney and other organs is notable. The best known is the relation with the cardiovascular system. Relationships with other organs are less studied, although their involvement sometimes dominates the clinical picture and the outcome of disease. The paper analyzes the kidney-liver relationship, namely chronic kidney disease and chronic liver disease from an immune viewpoint. The immune system operates as a unitary whole. There is an interdependence between the immune system of the liver, considered a lymphoid organ, and the kidney, whose participation in immune processes is well-known. The most important chronic liver diseases are viral hepatitis B and C. Infection with these viruses can lead to renal involvement, producing mainly glomerular disease. At the same time, secondary glomerulonephritis can cause an unfavorable outcome of the primary disease. The relationship between chronic liver disease and chronic kidney disease during chronic B and C hepatitis occurs via circulating immune complexes or complexes formed in situ. Cell-mediated immunity is also involved. The antiviral treatment of B and C hepatitis is also aimed at secondary glomerular disease. The participation of immune mechanisms raises the question of administering immunomodulating medication, a type of medication that influences viral replication--this is why it is associated with antiviral medication. Other two chronic liver diseases, namely liver cirrhosis, in which the main mechanism is a toxic one, and non-alcoholic steatohepatitis can produce via immune mechanisms glomerular involvement. In its turn, chronic kidney disease in advanced stages causes lipid metabolism disturbances with hypertriglyceridemia, which can influence fatty loading of the liver in the above-mentioned liver diseases. One can speak about a cross-talk between the liver and the kidney, in which immune mechanisms play an important role.
- Published
- 2015
- Full Text
- View/download PDF
44. Proximal tubule dysfunction is associated with podocyte damage biomarkers nephrin and vascular endothelial growth factor in type 2 diabetes mellitus patients: a cross-sectional study.
- Author
-
Petrica L, Vlad A, Gluhovschi G, Gadalean F, Dumitrascu V, Gluhovschi C, Velciov S, Bob F, Vlad D, Popescu R, Milas O, and Ursoniu S
- Subjects
- Albuminuria metabolism, Creatinine urine, Cross-Sectional Studies, Enzyme-Linked Immunosorbent Assay, Fanconi Syndrome etiology, Hepatitis A Virus Cellular Receptor 1, Humans, Membrane Glycoproteins urine, Membrane Proteins urine, Receptors, Virus, Vascular Endothelial Growth Factor A urine, Biomarkers metabolism, Diabetes Mellitus, Type 2 complications, Fanconi Syndrome diagnosis, Fanconi Syndrome pathology, Podocytes metabolism
- Abstract
Background: There is an ongoing debate as to whether early diabetic nephropathy in Type 2 diabetes mellitus may be attributed to the glomerulus or to the proximal tubule. Urinary excretion of nephrin and vascular endothelial growth factor may increase even in the normoalbuminuria stage. In the course of diabetic nephropathy, the proximal tubule may be involved in the uptake of urinary nephrin and vascular endothelial growth factor., Materials and Methods: Two groups of consecutive Type 2 diabetes mellitus outpatients (38 normo-, 32 microalbuminuric) and 21 healthy subjects were enrolled in a cross-sectional study and evaluated concerning the relation of proximal tubule dysfunction with the podocyte biomarkers excretion, assessed by ELISA methods. The impact of advanced glycation end-products on this relation was also queried., Results: Urinary alpha1-microglobulin and kidney injury molecule-1 correlated with urinary albumin:creatinine ratio (R2 = 0.269; p < 0.001; R2 = 0.125; p < 0.001), nephrinuria (R2 = 0.529; p<0.001; R2 = 0.203; p < 0.001), urinary vascular endothelial growth factor (R2 = 0.709; p < 0.001; R2 = 0.360; p < 0.001), urinary advanced glycation end-products (R2 = 0.578; p < 0.001; R2 = 0.405; p < 0.001), serum cystatin C (R2 = 0.130; p < 0.001; R2 = 0.128; p<0.001), and glomerular filtration rate (R2 = 0.167; p < 0.001; R2 = 0.166; p < 0.001); nephrinuria and urinary vascular endothelial growth factor correlated with urinary albumin:creatinine ratio (R2 = 0.498; p < 0.001; R2 = 0.227; p<0.001), urinary advanced glycation end-products (R2 = 0.251; p < 0.001; R2 = 0.308; p < 0.001), serum cystatin C (R2 = 0.157; p < 0.001; R2 = 0.226; p < 0.001), and glomerular filtration rate (R2 = 0.087; p = 0.007; R2 = 0.218; p < 0.001)., Conclusions: In Type 2 diabetes mellitus there is an association of proximal tubule dysfunction with podocyte damage biomarkers, even in the normoalbuminuria stage. This observation suggests a potential role of the proximal tubule in urinary nephrin and urinary vascular endothelial growth factor processing in early diabetic nephropathy, a fact which could be related to advanced glycation end-products intervention. Podocyte damage and proximal tubule dysfunction biomarkers could be validated as a practical approach to the diagnosis of early diabetic nephropathy by further studies on larger cohorts.
- Published
- 2014
- Full Text
- View/download PDF
45. Immunohistochemical study of tubular epithelial cells and vascular endothelial cells in glomerulonephritis.
- Author
-
Bob F, Gluhovschi G, Herman D, Petrica L, Bozdog G, Gluhovschi C, Velciov S, Gadalean F, Timar R, Potencz E, Dema A, and Schiller A
- Subjects
- Actins biosynthesis, Adolescent, Adult, Aged, Biomarkers, Endothelial Cells metabolism, Female, Glomerulonephritis metabolism, Humans, Immunohistochemistry, Male, Middle Aged, Retrospective Studies, Transforming Growth Factor beta biosynthesis, Vimentin biosynthesis, Young Adult, Epithelial Cells metabolism, Glomerulonephritis pathology, Kidney Tubules pathology
- Abstract
Background and Aims: In order to assess the role played by tubular epithelial cells (TEC) and interstitial vascular endothelial cells (VEC) in interstitial fibrogenesis in human glomerulonephritis, we studied the expression of markers of activated fibroblasts (α-smooth muscle actin (αSMA) and vimentin (Vim)) and of the transforming growth factor β (TGFβ), at the level of these cells., Methods: We studied retrospectively 41 renal biopsies from patients with primary and secondary glomerulonephritis [24 males, 17 females, mean age 45.5 ± 12.9 years]. Immunohistochemistry using monoclonal antibodies (SMA, Vim, TGFβ) was assessed using a semiquantitative score, that was correlated with biological and histological data (quantified using a scoring system in order to assess active-inflammatory and chronic-sclerotic/fibrotic lesions)., Results: The presence of SMA and Vim as markers of myofibroblasts was found in TECs and VECs. TEC Vim expression correlated with interstitial Vim expression (r = 0.38; p = 0.008), interstitial infiltrate (r = 0.31; p = 0.027), interstitial fibrosis (R = 0.25; p = 0.042), GFR (r = -0.35; p = 0.016), SMA (r = -0.42; p = 0.015), TGFβ (r = 0.25; p = 0.046), and hemoglobin (r = -0.55; p < 0.001). VEC Vim expression showed indirect correlations with interstitial infiltrate (r = -0.32; p = 0.023) and interstitial fibrosis (r = -0.34; p = 0.017)., Conclusion: Our study reflects the complexity of the involvement of VEC and mainly of TEC in fibrosis. The expression of mesenchymal markers at the tubular cell level (especially Vim) correlates with histological interstitial changes, with the decrease of renal function and more strongly with anemia.
- Published
- 2014
- Full Text
- View/download PDF
46. Urinary biomarkers in assessing the nephrotoxic potential of gentamicin in solitary kidney patients after 7 days of therapy.
- Author
-
Gluhovschi G, Gadalean F, Gluhovschi C, Velciov S, Petrica L, Bob F, Bozdog G, and Kaycsa A
- Subjects
- Adult, Biomarkers urine, Female, Glomerular Filtration Rate, Humans, Kidney abnormalities, Kidney Diseases urine, Kidney Tubules, Proximal drug effects, Male, Middle Aged, Nephrectomy, Acetylglucosaminidase urine, Alpha-Globulins urine, Anti-Bacterial Agents adverse effects, Gentamicins adverse effects, Kidney Diseases chemically induced, Kidney Diseases diagnosis, Urinary Tract Infections drug therapy
- Abstract
Introduction: The solitary kidney (SK) may present increased vulnerability to nephrotoxicity because of adaptive phenomena., Aims: Assessing the vulnerability of the SK with urinary tract infections (UTI) to gentamicin by means of urinary biomarkers (N-acetyl-beta-D-glucosaminidase (NAG) and urinary alpha-1-microglobulin), as well as glomerular filtration rate (GFR)., Methods: We studied 14 patients with SK with UTI (group A) (mean age 58.07 ± 13.61 years, mean duration of SK 13.55 ± 12.33 years) who were administered gentamicin for 7 days. Group B consisted by 17 patients with SK without any other associated renal pathology (average age 51.17 ± 9.39 years, average existence period of a single kidney 33.23 ± 21.73 years). We also included a third group (group C) represented by nine healthy individuals, with two kidneys., Results: Increased values of urinary NAG were found in group B as compared to group C and alpha-1 microglobulin in group A as compared to group B. During treatment with gentamicin, increased values of both NAG and alpha-1-microglobulin in group A were found on day 7 as compared to values before treatment (day 7 NAG=18.99 ± 14.07 U/g creat versus day 0, NAG=5.15 ± 6.54 U/g creat, p=0.004; day 7 alpha-1-microglobulin=20.88 ± 18.84 mg/g creat versus day 0, urinary alpha-1-microglobulin=4.96 ± 6.57 mg/g creat, p=0.003). No statistically significant alterations of GFR were noticed after 7 days of treatment., Conclusions: We found the nephrotoxic effects of gentamicin at tubular level, but not at glomerular level. The nephrotoxic potential of gentamicin in patients with a SK can be monitored by assessing urinary biomarkers during treatment of UTI.
- Published
- 2014
- Full Text
- View/download PDF
47. Aspects of renal-pulmonary pathogenic replationships in chronic kidney disease and chronic pulmonary diseases--a less-known connection.
- Author
-
Gluhovschi G, Velciov S, Petrica L, and Gluhovschi C
- Subjects
- Amyloidosis complications, Autoimmune Diseases complications, Chronic Disease, Dust, Glomerulonephritis etiology, Glomerulonephritis immunology, Hemorrhage etiology, Hemorrhage immunology, Humans, Hypertension, Pulmonary complications, Kidney Failure, Chronic complications, Kidney Failure, Chronic therapy, Kidney Transplantation, Lung Diseases etiology, Lung Diseases immunology, Occupational Exposure adverse effects, Renal Dialysis adverse effects, Renal Insufficiency, Chronic etiology, Silicon Dioxide adverse effects, Vasculitis complications, Lung Diseases complications, Renal Insufficiency, Chronic complications
- Abstract
The kidneys, as an integral part of the body, are in close functional relationship with other organs. Dysfunction of the relationship with one organ will affect the kidney. Chronic kidney disease (CKD) leads in time to alteration of the relationship of the kidney with other organs, sometimes with severe consequences. Thus, cardiovascular involvement in CKD leads to increased severity of CKD, with an increase in mortality rate. At present, the relationship between the kidney and the lung has been less studied. Many aspects of this relationship are still unknown. The objective of the present paper is to analyze the main situations of the alteration of the kidney-lung relationship in clinical pathology, with special reference to chronic kidney disease. The pulmonary-renal syndrome is at the forefront. This pathology--well known in practice--refers mainly to the kidney-lung relationship in vasculitis, systemic lupus erythematosus and Goodpasture's syndrome. The relationship between the kidney and the lung is not limited to this syndrome. Many systemic diseases like sarcoidosis and amyloidosis alter the lung-kidney binomial. Likewise, the association in some patients of an important disorder primarily affecting the lung, such as silicosis, with concomitant renal involvement, highlights the relationship between the lungs and kidneys in clinical pathology. It is very important to know heart-kidney relationships via the lung in pulmonary arterial hypertension. In-depth knowledge of the patient with chronic kidney disease also requires thorough analysis of the lung-kidney relationship. This relationship is very evident in haemodialysed patients, taking into consideration that the pulmonary circulation is influenced by the dialysis membranes, in patients on peritoneal dialysis and especially in transplanted patients whose kidney-lung relationship has a favorable outcome. Although little dealt with, the relationship between the kidneys and the lungs requires more attention, as it can have important consequences, and appropriate therapy.
- Published
- 2014
48. Surprising good antioxidant status in patients with Balkan Endemic Nephropathy on hemodialysis undergoing vitamin C therapy. A pilot study.
- Author
-
Gluhovschi C, Modilcă M, Margineanu M, Gluhovschi G, Velciov S, Petrica L, Barzuca E, Gădălean F, Ivascu S, Kaycsa A, and Ghiocel C
- Subjects
- Aged, Balkan Nephropathy physiopathology, Child, Female, Humans, Male, Middle Aged, Oxidative Stress, Pilot Projects, Renal Dialysis, Antioxidants metabolism, Ascorbic Acid therapeutic use, Balkan Nephropathy blood, Balkan Nephropathy therapy
- Abstract
Aims: End Stage Renal Disease (ESRD) represents a microinflammatory state accompanied by oxidative stress and an imbalance between pro- and antioxidants. Vitamin C is a highly effective antioxidant, acting to lessen oxidative stress. The aim of our study was to assess the Antioxidant Capacity of Water soluble substances (ACW) and the Antioxidant Capacity of Liposoluble substances (ACL) in patients with Balkan Endemic Nephropathy (BEN) on hemodialysis undergoing Vitamin C therapy as compared to healthy controls., Methods: Twenty-one patients with BEN on hemodialysis (HD), mean age: 63.33 +/- 5.42 years, 6 M and 15 F, were enrolled into the study. All patients received 10 vials of Vitamin C 750 mg/5 ml every 2 months. Eleven apparently healthy subjects, mean age: 63.73 +/- 5.21 years, 6 M and 5 F, served as controls. The photochemiluminescence assay was used to measure the antioxidant activity of plasma samples. The results are presented in equivalent concentration units of Vitamin C for water soluble antioxidants and in equivalent concentration units of Trolox (synthetic Vitamin E) for lipid soluble antioxidants. Both concentrations are expressed in micromols/L. Statistical analysis (non-parametric Wilcoxon test) was performed using NCSS., Results: Mean duration since BEN diagnosis was: 8.24 +/- 3.5 years. Mean duration since HD initiation was: 4.92 +/- 3.4 years. Smoking status was negative in all patients. Hypertension was present in 15 patients (71.42%), cardiovascular disease in 10 (47.61%), HCV infection in 13 (61.9%), 1 patient had HBV + HCV infection, 1 had renal tuberculosis, 1 had upper urinary tract cancer, 1 genital cancer, and I autoimmune thyroid disease. The Antioxidant Capacity of Water soluble substances (ACW) in patients with BEN was 477.6 +/- 177.63 micromols/L, significantly higher as compared to controls: 198.05 +/- 196.63 micromols/L; p = 0.01, whereas the Antioxidant Capacity of Liposoluble substances (ACL) in patients with BEN was 33.9 +/- 22.99 micromols/L, non-significantly different as compared to controls: 27.38 +/- 4.21 micromols/L; p = 0.22., Conclusions: We conclude that Vitamin C therapy in patients with BEN on HD significantly increases the Antioxidant Capacity of Water soluble substances (ACW) as compared to controls and could be used to counter oxidative stress in patients with ESRD.
- Published
- 2014
49. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania.
- Author
-
Gluhovschi G, Mateş A, Gluhovschi C, Golea O, Gădălean F, Somai M, Ene I, Petrica L, and Velciov S
- Subjects
- Adult, Aged, Angiotensin Receptor Antagonists adverse effects, Angiotensin-Converting Enzyme Inhibitors adverse effects, Antihypertensive Agents adverse effects, Female, Glomerular Filtration Rate, Humans, Hyperkalemia chemically induced, Hyperkalemia diagnosis, Kidney Failure, Chronic physiopathology, Kidney Failure, Chronic therapy, Male, Middle Aged, Renal Dialysis, Romania, Severity of Illness Index, Hyperkalemia blood, Kidney Failure, Chronic blood, Potassium blood
- Abstract
Unlabelled: CKD patients present deficient elimination of potassium. Ambulatory treatment with hypotensors, mainly angiotensin-renin system inhibitors, can be associated in these patients with potassium retention and risk of hyperkalemia. In pre-dialysis stage-5 CKD patients, the use of medication accompanied by hyperkalemia increases risks of developing it. Using diuretics like spironolactone also increases this risk. Serum potassium can also increase in case of inappropriate consumption of potassium-rich food (bananas). Since ambulatory care does not always rigorously control hyperkalemia in CKD patients we consider it is useful to screen patients when they are referred to dialysis services. The screening can reflect the management of ambulatory CKD patients under treatment with ACE-I and ARB hypotensors. We remark that beta-blockers are attributed a (limited) role in increasing the values of serum K., Material and Method: We studied a group of 477 stage-5 CKD patients referred for dialysis to The Dialysis Centre of the Emergency County Hospital Timişoara. The average age of the patients was 57.41 +/- 14.26 years. 260 were males and 217 females. All were stage-5 CKD with GFR < 15 mL/min/1.73 m2, with a group average value of eGFR of 5.72 +/- 2.81 mL/min/1.73m2. Our investigations showed hypokalemia in 14 patients (2.93%). Hyperkalemia was found in 179 patients. Of these, 124 had mild hyperkalemia (5.5-6.4 mEq/L), 45 patients had medium hyperkalemia (6.5-7.5 mEq/L) and 10 (2.09%) had severe hyperkalemia (K > 7.5 mEq/L)., Discussion: Hyperkalemia was more frequent in patients who had been treated with blockers of the renin-angiotensin system than in patients who had used other hypotensors or who had not needed hypotensors and had not taken diuretics. Severe hyperkalemia (K > 7.5 mEq/L) was present both in patients treated with blockers of the renin-angiotensin system and in those treated with other hypotensors and in 1 case without hypotensor or diuretic treatment. 2 cases treated with blockers of the renin-angiotensin-aldosterone system with severe hyperpotassemia associated antialdosteronic diuretics, cumulating hyperpotassemic effects. Diuretic treatments with loop diuretics influenced the values of serum K of most patients. Hyperkalemia represents an important problem in nephrology because of the risks it induces in the treatment ofpre-dialysis CKD patients and it requires attentive monitoring.
- Published
- 2014
50. Are other factors besides albuminuria important for the progression of HCV chronic hepatitis towards CKD? A survey from a hepatology department in western Romania.
- Author
-
Gluhovschi C, Sporea I, Gădălean F, Kaycsa A, Curescu M, Velciov S, Petrica L, Bălgrădean C, Vernic C, and Gluhovschi A
- Subjects
- Adult, Female, Glomerular Filtration Rate, Hepatitis C, Chronic urine, Humans, Hypercholesterolemia complications, Hypertension complications, Male, Middle Aged, Obesity complications, Renal Insufficiency, Chronic physiopathology, Renal Insufficiency, Chronic urine, Risk Factors, Romania, Albuminuria virology, Hepatitis C, Chronic complications, Renal Insufficiency, Chronic virology
- Abstract
Unlabelled: HCV is an important cause of renal disease. Taal and Brenner have identified risk factors for CKD and have suggested that these risk factors be incorporated into a renal risk score analogous to the Framingham cardiovascular score. Given the high HCV-renal disease comorbidity, we sought to assess risk factors for CKD in patients with HCV chronic hepatitis., Methods: One hundred-seventeen patients with HCV chronic hepatitis (mean age: 50.68 +/- 9.14 years; 86 female and 31 male) hospitalized in the Department of Hepatology during 2009 were enrolled into the study. All patients were assessed for the risk factors for CKD proposed by Taal and Brenner: albuminuria, diabetes mellitus, hypertension, obesity, anemia, hypercholesterolemia, hypertriglyceridemia, nephrotoxins, primary renal disease, associated urological disorder, cardiovascular disease and family history of CKD. Renal function (GFR-CKD-Epi) was also evaluated., Statistical Analysis: Pearson's correlation coefficient and Odds Ratio (OR) was performed using SPSS17 and Epi 3.2.2., Results: The prevalence of albuminuria was 21.36%, of hypertension was 20.51%, of obesity was 21.36%, and hypercholesterolemia was present in 41.02% of the cases. Renal function was as follows: 10.25% (12/117) of the patients had a GFR < 60 mL/min/1.73 sqm.; 64.95% (76/117) of the patients had a GFR between 60-89 mL/min/1.73 sqm.; and 24.78% (29/117) had a GFR > or = 90 mL/min/1.73 sqm., Conclusions: Our study shows that HCV chronic hepatitis is associated with renal function impairment in a high percentage of patients. Prominent risk factors for CKD are present in these patients, such as albuminuria, hypertension, obesity, and hypercholesterolemia, which need to be actively searched and addressed therapeutically.
- Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.